EP0902696B1 - Cartridge-based drug delivery device - Google Patents

Cartridge-based drug delivery device Download PDF

Info

Publication number
EP0902696B1
EP0902696B1 EP96945772A EP96945772A EP0902696B1 EP 0902696 B1 EP0902696 B1 EP 0902696B1 EP 96945772 A EP96945772 A EP 96945772A EP 96945772 A EP96945772 A EP 96945772A EP 0902696 B1 EP0902696 B1 EP 0902696B1
Authority
EP
European Patent Office
Prior art keywords
cartridge
skin
drug
needle
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96945772A
Other languages
German (de)
French (fr)
Other versions
EP0902696A1 (en
Inventor
Joseph Gross
Gilad Lavi
Izrail Tsals
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Corp PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Publication of EP0902696A1 publication Critical patent/EP0902696A1/en
Application granted granted Critical
Publication of EP0902696B1 publication Critical patent/EP0902696B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/145Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
    • A61M5/1452Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
    • A61M5/14526Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons the piston being actuated by fluid pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/145Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
    • A61M5/1452Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
    • A61M5/1454Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons spring-actuated, e.g. by a clockwork
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • A61M2005/14252Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type with needle insertion means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • A61M2005/1426Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type with means for preventing access to the needle after use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/158Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
    • A61M2005/1581Right-angle needle-type devices

Definitions

  • This invention relates to devices for subcutaneous, intravenous, intramuscular or intradermal delivery of drugs to a subject.
  • syringes are not generally advocated for use in self administration by patients because of the dangers of embolisms arising from the introduction of air bubbles into the bloodstream, incorrect dosing, and the accidental infection of third parties after use of the syringe. In any event, syringes cannot be used by children or by many elderly patients, and the use of syringes is very traumatic for the large number of people who are needlephobic to a greater or lesser extent.
  • the device of U.S. Patent No. 3,527,212 eliminates the use of needles and has a construction with fewer parts, but manufacture would still be difficult and expensive as the needleless injection of a drug requires the drug to be provided to the skin at pressures in excess of 400 lb/in 2 (27.5 ⁇ 10 5 Pa).
  • the device must be provided with a propellant at such a pressure when it is manufactured, and this pressure must be maintained throughout the shelf life of the device in a compartment which is bounded by a membrane strong enough to withstand the pressure but which is nevertheless easily rupturable by the manual depression of a plunger.
  • these requirements lead to a product which is quite difficult and expensive to manufacture.
  • Needleless devices have their own problems, since their correct use requires a certain degree of dexterity and strength.
  • the device must be held firmly against the skin at the correct angle. Correct delivery of the drug requires it to be propelled at high pressure through the skin, so if the device is held at an incorrect angle or is not held firmly enough, then there is a strong likelihood that the medicament will not pass through the skin but will be dispersed into the air.
  • needleless injectors are usually quite bulky, the dexterity issue may be far from trivial from many patients.
  • each of the devices referred to above can only be used for bolus administration, i.e. the immediate injection of a single entire dose. This is not suitable for all therapies, as it may be preferred in many cases to provide a continuous infusion of a drug both to avoid toxicity problems and to provide improved efficacy. Furthermore, if a drug is provided as a bolus injection, it may be necessary to inject a number of doses per day.
  • infusion pumps A number of infusion pumps are known, such as those described in U.S. Patent No. 4,886,499 and our own WO 95/13838. In general, however, infusion pumps are far more sophisticated and complex than syringes or syringe-based injectors, with the result that they are unable to compete commercially with conventional injectors.
  • U.S.-A-2 605 765 describes an automatic syringe for continuously and automatically administering medicinal compositions in fluid form to the body of a patient.
  • the syringe comprises a housing provided with a variable volume chamber having a discharge passage leading to a hollow injection needle which extends approximately at right angles with respect to the bottom surface of the housing.
  • the injection needle is protected by a removable cap.
  • the fluid is expelled from the syringe by a power piston arrangement following removal of the protecting cap from the injection needle. Shortly before the device is applied, the power piston is primed for action.
  • a drug delivery device which: is capable of delivering a pre-set dosage of drug to a subject; is suitable for use in self-administration by patients (including young patients and elderly patients); does not require the patient to consciously insert a needle into the skin; has a construction sufficiently simple to enable it to be mass produced at least as cheaply as (and in most cases more cheaply than) prior art bolus injectors described in the documents referred to above and substantially more cheaply than prior art infusion pumps; can provide either a bolus injection or can perform a continuous or controlled infusion; and overcomes the disadvantages associated with the conventional hypodermic syringe. Further objects and advantages of the invention will become apparent from the description given below.
  • the invention provides a liquid drug delivery device comprising a base member defining a skin-contacting surface for application to the skin of a subject, a columnar cartridge serving as reservoir for the drug and which is connected to the base member such that in use the longitudinal axis of the cartridge is disposed substantially parallel to the skin-contacting surface, a delivery needle communicating in use with the interior of the cartridge and adapted to penetrate the skin of the subject, and means for expelling a drug out of the interior of the cartridge and through the skin of the subject via the delivery needle, characterised in that the connection between the cartridge and the base member allows relative movement therebetween from an initial configuration to a working configuration and is provided by a ginge enabling the cartridge and the base member to be pressed towards one another from a spaced-apart initial configuration to an adjacent working configuration.
  • the device can be applied to the skin in order to effect delivery of the drug.
  • a conventional columnar cartridge such as a refill cartridge of the type used in "pen-type" insulin injectors, or it can be any other type of columnar cartridge.
  • Such cartridges may suitably be cylindrical glass or plastic cartridges, for example, and would preferably be extremely inexpensive to manufacture.
  • the configuration of the device means it can be applied to the skin, and delivery can be effected in a single step application, as will be described below.
  • the configuration which uses a skin-contacting surface and a delivery needle which penetrates the skin of the subject means that far less dexterity is required in administering the drug than is the case with many bolus injectors, including those referred -to previously.
  • carrier denotes a columnar container or vessel for a liquid, preferably formed of glass or plastic.
  • carrier does not necessarily imply a component which is removable from the device as a whole, or a component which is replaceable, although the cartridge may in fact be removable or replaceable.
  • liquid drug includes drugs which are in the form of liquids, solutions, suspensions, or flowable gels.
  • a portion of the interior of the cartridge defines a drug compartment for the drug, the drug being expelled from the compartment by a piston actuated by the expelling means.
  • the columnar cartridge may be cylindrical or it may be of generally cylindrical form (the cross section need not be circular). Indeed, one can envisage cases where a cylinder having a slight longitudinal curve would be employed for design reasons. Such cartridge shapes are perfectly acceptable provided of course that the piston is still effective to expel the drug from the drug compartment.
  • the interior of the cartridge also defines a chamber housing the expelling means, such that the actuation of the piston by the expelling means causes the expansion of said chamber and the contraction of said drug compartment.
  • the cartridge (which may be as simple as a glass or plastic cylinder) can house both the drug and the expelling means. Indeed, a number of embodiments described in detail below illustrate this arrangement.
  • the expelling means into the cartridge, one obtains significant savings in space, thereby making the device as small and unobtrusive as possible. This is particularly important if the device is to be worn for an extended period of time.
  • the expelling means is incorporated within the cartridge but the chamber containing the expelling means is in fact also the drug compartment and the expelling means serve to pull the piston and contract the chamber (and drug compartment).
  • the expelling means must be sterile and inert if it is in contact with the drug.
  • the piston it is preferable to use the piston to separate an expansible chamber for the expelling means and a contractible drug compartment for the drug.
  • the device is provided with a conduit enabling fluid communication to be established in use between the drug compartment and the delivery needle.
  • the conduit extends at substantially right angles from the delivery needle.
  • the conduit can access the drug compartment through an end of the cartridge (in a direction purposely parallel to the skin-contacting surface), and the delivery needle can deliver drug passing out of the drug compartment through the conduit by penetrating normally through the skin.
  • an angle of exactly 90° is not required (although it may be preferred), but one would envisage that the conduit extends from the delivery needle at 80-100°, preferably 85-95° (and most preferably 90°). This allows the needle to penetrate the skin vertically and simultaneously allows communication to be established between this delivery needle and a cartridge lying exactly parallel to the skin.
  • the conduit is integral with the delivery needle.
  • the delivery needle and the conduit form part of a needle assembly mounted on an end of the cartridge.
  • the device further comprises a mechanism for actuating the expelling means.
  • connection between the cartridge and the base member allows relative movement therebetween from an initial configuration to a working configuration.
  • said relative movement operates the mechanism for actuating the expelling means.
  • the device can be in an initial configuration in which it is maintained during storage or before use, and then by moving the cartridge and base member relative to one another, the device is primed for use and the expelling means is actuated.
  • said relative movement causes the delivery needle to project through the plane of the skin-contacting surface and thereby penetrate the skin in use.
  • This arrangement allows the skin-contacting surface to be placed on the skin (this surface being suitably provided with an adhesive coating or the device being provided with some other means of retaining the skin-contacting surface on the skin), and then a relative movement between the base member and the cartridge causes the penetration of the skin (and optionally, the actuation of the expelling means).
  • said relative movement causes the establishment of fluid communication between the drug compartment and the delivery needle.
  • the relative movement between the cartridge and base member accomplishes all three preferred acts, namely the actuation of the expelling means, the penetration of the skin by the delivery needle and the establishment of fluid communication between the drug compartment and the delivery needle, then one can achieve a single-step application of the device, whereby some movement between the cartridge and the base member achieves the delivery of drug in a safe and predictable manner.
  • the relative movement may be rotational or translational.
  • the cartridge could be incorporated in a first section of a housing which is screwed relative to a second section of the housing (the second section incorporating the base member), with this screwing movement initiating delivery.
  • the skin-contacting surface is provided with an aperture through which the delivery needle extends in use.
  • the needle can be retracted in the initial configuration and it can extend through the skin-contacting surface in the working configuration; this allows for a device in which the needle is never seen by the subject in normal use. This is particularly suitable for needlephobics or people who, while not actually needlephobic, are upset to a greater or lesser degree by needles and injections.
  • an end of the cartridge is provided with a stopper and the conduit and stopper are movable relative to one another to allow the conduit to penetrate through the stopper and thereby establish said communication.
  • the conduit can be pointed or blunt, provided that it is able to penetrate through and establish communication with the interior of the cartridge.
  • This arrangement is advantageous because it allows the contents of the drug compartment to be maintained in a sterile condition until the moment when communication is established between the delivery needle and the drug compartment.
  • the device can be applied to the skin and a -single action can cause establishment of communication between the delivery needle and the cartridge at roughly the same moment as the delivery needle penetrates the skin.
  • the skin-contacting surface may be covered before use by a release liner of some sort.
  • the position of the needle assembly is fixed with respect to the cartridge, and the stopper is movable relative to both the cartridge and the needle assembly.
  • the actuation of the expelling means causes the stopper to be pressed onto and penetrated by the conduit.
  • the position of the stopper is fixed with respect to the cartridge, and the needle assembly is movable relative to both the cartridge and the stopper.
  • the expelling means comprises a pre-compressed spring.
  • the mechanism for actuating the expelling means comprises a catch which when released enables the pre-compressed spring to relax.
  • a relative movement between the cartridge and the base member from an initial configuration to a working configuration causes the catch to be released.
  • the expelling means comprises a gas generator which generates a gas when two or more reactants are brought into contact.
  • the gas generator comprises at least one liquid.
  • the gas generator comprises the components of an effervescent couple.
  • the expelling means comprises a material which swells in the presence of a liquid, and also comprises a supply of said liquid.
  • said material is a swellable gel and said liquid is water.
  • the expelling means comprises a liquid as an essential component
  • said liquid is contained within a rupturable compartment and the mechanism for actuating the expelling means comprises a penetrating member, the penetrating member and the rupturable compartment being moved relative to one another upon the relative movement of the cartridge and the base member , so as to cause the penetration of said rupturable compartment and the actuation of the expelling means.
  • the device further comprises a snap mechanism which maintains a stable initial configuration and a stable working configuration and which when actuated causes the device to snap from said initial configuration to said working configuration.
  • the device is provided with resilient means biasing the device to said initial configuration and means for disengaging said snap mechanism when delivery has been completed.
  • said disengaging means comprises a member linked to said piston such that when the piston has completed the expulsion of drug from the drug compartment, said member is caused to move and said movement causes the disengagement of said snap mechanism, such that said resilient means causes the device to resume said initial configuration.
  • the automatic release of the snap mechanism after completion of delivery causes the spring to return the device to the initial configuration (being no longer held in the working configuration by the snap mechanism).
  • this movement will cause the retraction of the delivery needle from the skin, optionally to a point where it is no longer visible.
  • This action (which might be observed by the cartridge snapping away from the base member) informs the subject that delivery has been completed and, in certain cases, retracts the needle to the point where it is concealed from the subject both before use and after use.
  • said relative movement is a pivotal movement.
  • said delivery needle projects through the plane of the skin-contacting surface at or outside of the periphery of the skin-contacting surface.
  • the delivery needle projects through the plane at a point on the periphery of the skin-contacting surface distal from the hinge, as this means that the needle will jab through the skin more quickly than it would if it was located right beside the hinge. The quicker the needle pierces the skin the less painful it is likely to be for the subject.
  • the delivery needle is in the shape of a segment of arc of an imaginary circle, said circle having a radius equal to the distance between the delivery needle and the hinge and lying in a plane which is substantially normal to the plane of the skin-contacting surface.
  • This embodiment with a curved needle is useful where the needle is unusually long, as a pivotal movement such as that provided by a hinge causes the needle to have a lateral component of velocity when it is penetrating the skin.
  • This lateral movement of the needle causes the stretching or tearing of the skin in extreme cases, and in any event leaves a bigger entry wound than would otherwise be the case.
  • the dimensions of the imaginary circle given above ensure that the body of the needle exactly follows the point of the needle on its path into the subject.
  • the delivery needle may be straight. This is preferred in embodiments in which delivery needle moves straight down into the skin, or in embodiments where the length of the delivery needle or the radius of the imaginary circle means that the needle has a negligibly small lateral component of movement upon entering the so skin that it would be uneconomical or unnecessary to make a curved needle. Indeed, in many cases, it will be unnecessary for the needle to be curved.
  • Typical medicaments suitable for use with the device according to the invention include peptides, proteins or hormones such as insulin, calcitonin, calcitonin gene regulating protein, atrial natriuretic protein colony stimulating factor, betaseron, erythropoietin (EPO), interferons such as a, b or g interferon, somatropin, somatotropin, somatostatin, insulin-like growth factor (somatomedins), luteinizing hormone release hormone (LHRH), tissue plasminogen activator (TPA), growth hormone releasing hormone (GHRH), oxytocin, estradiol, growth hormones, leuprolide acetate, factor VIII, interleukins such as interleukin-2, and analogues thereof; analgesics such as fentanyl, sufentanil, butorphanol, buprenorphine, levorphanol, morphine, hydromorphone, hydrocodone, oxy
  • a cartridge-based drug delivery device in the form of a body 11 comprising a cartridge 12 and a member 13 defining a skin contacting surface 14.
  • Surface 14 is covered by a release liner 15 before use.
  • a piston 16 is contained in cartridge 12 and defines on one side thereof a drug compartment 17 and on the other side thereof a driving chamber 18. Compartment 17 is filled with a liquid drug and is sealed at the end opposite piston 16 by a stopper 19.
  • a needle assembly 20 is mounted on cartridge 12. Needle assembly 20 has a hollow delivery needle 21 extending therefrom, and delivery needle 21 is provided with communication means in the form of a conduit needle 22. As illustrated in Fig. 1, conduit needle 22 penetrates into but not through stopper 19 before use.
  • a spring 23 is held under compressed tension by a rod 24 having a plate 25 at one end thereof and a catch projection 26 at the other end thereof.
  • Rod 24 extends through an orifice 26a in a wall section 27 and catch projection 26 is retained by wall section 27 such that spring 23 is held under tension as long as catch projection 26 remains in position.
  • Plate 25 abuts against piston 16.
  • Cartridge 12 is connected to member 13 by means of a living hinge 28.
  • a simple snap mechanism (not shown) causes device 10 to remain in the configuration illustrated in Fig. 1 until cartridge 12 and member 13 are compressed together giving rise to the working configuration illustrated in Fig. 2.
  • An aperture 29 in skin-contacting surface 14 allows needle 21 to project therethrough, thereby permitting cartridge 12 and member 13 to be pressed together such that, in use, cartridge 12 lies substantially flat against skin-contacting surface 14.
  • Fig. 3 shows a perspective view of device 10 in the same configuration, in which body 11, cartridge 12, member 13, release liner 15, piston 16, needle assembly 20 and aperture 29 can be seen.
  • release liner 15 is peeled away from skin-contacting surface 14, and skin contacting surface 14 is then placed against the skin to which it adheres by means of an adhesive coating.
  • Downward pressure is then exerted on the upper surface 30 (see Fig. 3) of body 11 causing cartridge 12 to be snapped towards member 13 by means of hinge 28 and the snap mechanism (not shown). Delivery needle 21 passes through aperture 29 and penetrates through the skin.
  • catch projection 26 rests against an abutment 31 before use.
  • Fig. 2 it can be seen that when cartridge 12 has been snapped towards skin contacting surface 14, wall section 27 moves relative to abutment 31. Because wall section 27 moves downwards and catch projection 26 is prevented from moving downwards by abutment 31, the relative movements of wall section 27 and catch projection 26 cause catch projection 26 to be dislodged enabling it to pass through orifice 26a in wall section 27, which it does readily as spring 23 is under compressed tension. Once catch projection 26 is released, spring 23 urges rod 24 to move towards the position shown in Fig. 2.
  • Removal of the device from the skin merely involves pulling body 11 upwards to remove delivery needle 21 from the skin, and peeling skin contacting surface 14 away from the skin.
  • the use of a snap mechanism means that cartridge 12 and member 13 disengage from one another (i.e. body 11 snaps back to its original configuration as illustrated in Figs. 1 and 3) before skin contacting surface 14 is peeled off the skin. This disengagement has the result that when removed, device 10 is harmless because delivery needle 21 has been retracted through aperture 29 and is thereby concealed, preventing accidental injury and possible risk of infection from delivery needle 21.
  • the release liner is peeled away to reveal a sterile adhesive surface.
  • the device is pressed against the skin by applying pressure to top surface 30. This act causes (i) the adhesion of skin contacting surface 14, (ii) the snapping together of cartridge 12 and member 13, (iii) the resulting dislodgement of catch projection 26, which leads to (iv) the penetration of stopper 19 by conduit needle 22 and (v) the delivery of the contents of compartment 17 through delivery needle 21.
  • body 11 is lifted away from the skin. This act causes the retraction of needle 21, thereby making the device safe for disposal.
  • All the patient has to do is: (a) peel away the release liner, (b) press the device against the skin, and (c) lift the device off the skin when delivery has been completed.
  • the completion of delivery can be observed by monitoring the movement of piston 16 along the length of cartridge 12 (see Fig. 3).
  • step (b) All of the steps relating to correctly administering a precise dosage of drug are accomplished by the single step (b), namely applying pressure to upper surface 30.
  • This simplicity opens up the possibility of self administration by patients who would be unable or unwilling to self administer a drug otherwise.
  • the configuration of device 10 not only ensures that the entire mechanism is activated by a single step, but it also compels the patient to administer the drug correctly.
  • the mechanism causes delivery needle 21 to penetrate the skin at the correct angle and to the correct depth, and since cartridge 12 is prefilled with a known volume of drug, the metering of the dose to be delivered is automatic and is removed from the patient's responsibility.
  • a further advantage provided by the device of Figs. 1-3 is that from the patient's point of view, the needle is invisible. This is a distinct advantage for subjects who are uncomfortable with the idea of injections and needles.
  • the diameter of the needle used in the embodiment of Figs. 1-3 is 0.25 mm, making it sufficiently small that it is effectively painless when it penetrates the skin. The internal diameter is nevertheless big enough to allow the delivery of macromolecular compounds such as peptides, polypeptides and proteins.
  • 1-3 does not entirely conceal delivery needle 21 (which can be seen by looking into the gap between member 13 and cartridge 12), a collar can be provided around the periphery of skin contacting surface 14 so as to conceal the needle at all times, if the visibility of the needle is a major concern.
  • a different embodiment of a drug delivery device there is indicated, generally at 40, a different embodiment of a drug delivery device according to the invention.
  • Device 40 is in many respects similar to device 10 of Figs. 1-3, but a different expelling means is employed and a different mechanism for actuating the expelling means is employed.
  • piston 41 is driven by gas pressure. Gas is generated by the reaction of a quantity of citric acid solution 42 with a sodium bicarbonate tablet 43.
  • device 40 is illustrated before use (a perspective view can be seen in Fig. 5).
  • Citric acid solution 42 is contained within a compartment defined by a rupturable membrane 44.
  • a solid needle 45 is disposed with its point immediately adjacent to membrane 44. Needle 45 projects from a wishbone structure 46 through a stopper 47. Stopper 47 and piston 41 form a sealed compartment such that the generation of gas causes piston 41 to move in the direction indicated by the arrow.
  • the gas generator 42,43,44 is actuated by pressing the cartridge 48 and member 49 (which defines a skin-contacting surface 50) together. In practice this is done by placing surface 50 against the skin and pressing downwards on upper surface 51 (see Fig. 5).
  • a pair of brackets 53 supporting wishbone structure 46 also approach one another.
  • Wishbone structure 46 is flexible, so the movement of the brackets 53 causes wishbone structure 46 to flex, thereby moving needle 45 in the direction indicated by the arrow. This movement ruptures membrane 44, thereby releasing citric acid 42 which contacts sodium bicarbonate 43 and generates a gas to provide a driving force equivalent to spring 23 of device 10 illustrated in Figs. 1-3.
  • FIGs. 6, 7 and 8 illustrate the device in sectional elevation
  • Figs. 9, 10 and 11 are perspective views of the device as illustrated in Figs. 6, 7 and 8, respectively.
  • the device indicated generally at 60 has many features in common with the devices previously described.
  • a cartridge 61 connected by a hinge 62 to a member 63 defining an adhesive skin-contacting surface 64.
  • a piston 65 defines a drug compartment 66 which is sealed by a stopper 67.
  • a needle assembly 68 is moveable with respect to cartridge 61 in the direction indicated by the arrow so as to pierce stopper 67 and thereby provide communication between drug compartment 66 and a delivery needle 69, as illustrated in Fig. 7.
  • a perforated polyethylene bellows 73 is wetted by the water released from compartment 72.
  • Bellows 73 is water permeable and is filled with a gel which swells in the presence of water, such as acrylite gels.
  • the choice of gel material determines to a large extent the rate of delivery.
  • the delivery rate is also affected by the permeability of the bellows.
  • the permeability of the bellows may be determined by the number and size of perforations or by the nature of the material (which may be water permeable) used for the bellows.
  • Figs. 6-11 The device of Figs. 6-11 is not shown to scale as the degree of expansion shown in Fig. 8 would not be achieved by a bellows and water compartment of the size shown in Figs. 6 and 7.
  • the principle of a permeable, gel-filled bellows expanding as water is absorbed by the gel is clear.
  • a freely permeable barrier 77 is provided between mounting member 70 and bellows 73.
  • Barrier 77 is fixed relative to the cartridge, and so when compartment 72 is pierced and bellows 73 begins to expand as it absorbs water, barrier 77 prevents bellows 73 from expanding backwards into the space formerly occupied by the water in compartment 72.
  • cartridge 61 is firmly mounted on mounting member 70, the seal between cartridge 61 and mounting member 70 is vacuum tied.
  • a small amount of leakage is allowed for, to allow air to be drawn into the space between mounting member 70 and barrier 77 as the water is drawn out of that space by absorption into bellows 73.
  • the degree of leakage is small enough, however, to prevent water from seeping out (this is perfectly possible given the differences in properties between water and air).
  • a gas-permeable, water impermeable material could be used for mounting member 70 (or a section thereof).
  • Expelling means 80 is again positioned at an end of a cartridge 81.
  • the expelling means 80 consists essentially of a fixed end cap 82 and a moveable end cap 83 which is slidable within cartridge 81 and which serves as a piston to compress drug compartment 84. Between them, the end caps 82,83 define a driving chamber which is filled with a swellable gel 85.
  • a flexible perforated spiral wound plastics tube 86 also extends within the space defined by the end caps 82,83, and tube 86 is in communication, in use, with a source of water (not shown) via an inlet 87 in end cap 82.
  • Figs. 13-15 illustrate a schematic diagram of a further embodiment of the invention.
  • the device indicated generally at 90 has many features in common with devices previously described.
  • a cartridge 91 slidably mounted on a mounting member 92 provided with penetrating means 93.
  • a piston 94 defines a drug compartment 95 on one side thereof and a driving chamber 96 on the other side thereof.
  • Driving chamber 96 contains a rupturable citric acid compartment 97 and a sodium bicarbonate tablet 98 such that when compartment 97 is penetrated by penetrating means 93, citric acid is released to sodium bicarbonate tablet 98 in order to generate a gas and drive piston 94 along cartridge 91.
  • a needle assembly 100 which has a hollow conduit needle 101 extending at right angles from a hollow delivery needle 102 is mounted on cartridge 91 such that movement of needle assembly 100 in the direction indicated by the arrow causes conduit needle 101 to pierce stopper 99, thereby establishing communication between drug compartment 95 and delivery needle 102.
  • Mounting member 92 is connected by a hinge to a base member 103 which defines a skin-contacting surface 104.
  • Base member 103 is provided with a lever mounting 105 on which a lever 106 is pivotally mounted. Actuation of lever 106 in the direction indicated by the arrow in Fig. 13 causes the device to assume the configurations shown in Fig. 14 (initially) and Fig. 15 (subsequently). Actuation of lever 106 pushes needle assembly 100 (to which lever 106 is pivotally mounted by means of a pivot 107) onto cartridge 91, and pushes cartridge 91 onto mounting member 92. This causes (a) the penetration of stopper 99 by conduit needle 101 and (b) the penetration of citric acid compartment 97 by penetrating means 93. As indicated in relation to previous embodiments, this has the effect of establishing communication between drug compartment 95 and delivery needle 102 and also of initiating the generation of gas which will drive piston 94 to expel the liquid drug from drug compartment 95.
  • lever 106 continues actuation of lever 106 to the position indicated in Fig. 15 causes needle 102 to penetrate into the skin. It will be appreciated that the actuation of lever 106 accomplishes the actuation of the expelling means, the establishment of communication between the drug compartment 95 and the delivery needle 102, and the correct penetration angle and depth of delivery needle 102 into the skin. Correct and fail-safe dosing is therefore inevitable.
  • Fig. 16 there is indicated, generally at 110 a device similar to that of Fig. 1.
  • the expelling means which drives the piston 111 along cartridge 112 comprises the spring 113 which acts on pusher plate 114 to drive the piston 111.
  • the spring 113 is held in place by rod 115 and catch projection 116 which extends through an orifice 117 in wall section 118.
  • catch projection 116 moves relative to orifice 117 because catch projection 116 is prevented from moving downwards by abutment 121.
  • Precompressed spring 113 causes catch projection 116 to move through orifice 117 and exerts a force on piston 111. As previously described in relation to the device of Figs. 1-3, this force causes a stopper 122 to pierce conduit needle 122a and then causes the ejection of drug from the interior of cartridge 112.
  • rod 115 is provided with first and second extension members 123, 124.
  • catch projection 116 serves to pull first extension member 123 forward and this in turn pulls the second extension member 124 forward.
  • the second extension member 124 is provided with a projection 125 which extends through an orifice 126 in abutment 121.
  • Projection 125 and orifice 126 act as a snap mechanism which is illustrated in greater detail in Figs. 18 and 19.
  • Fig. 18 shows a sectional elevation through the line A-A in Fig. 17. In Fig. 18 abutment 121, projection 125 and orifice 126 can been seen.
  • FIG. 19 shows projection 125 and orifice 126 in greater detail. It can be seen that orifice 126 is provided with a pair of resilient teeth 127. These teeth allow projection 125 to move from the initial position as shown in Fig. 16 (and indicated in dotted outline in Fig. 19 by reference numeral 125') to the working position shown in Fig. 17 (indicated by reference numeral 125 in Fig. 19).
  • device 110 is applied to the skin and top surface 120 is pressed downwards, projection 125 snaps from position 125' to the position shown in Fig. 19.
  • a spring 128 resists this downward movement. However, once projection 125 has snapped downwards, resilient teeth 127 prevent projection 125 from moving back up under the urging of spring 128.
  • Fig. 20 it can be seen that when piston 111 moves to its final position, catch projection 116 pulls first extension member 123 and second extension member 124 forwards to a sufficient extent that projection 125 is pulled forward and dislodged from orifice 126. This disengages the snap mechanism and allows cartridge 112 to move away from base member 119 under the influence of spring 128, to the position illustrated in Fig. 20. This has the effect of disengaging the delivery needle 129 from the skin and retracting it to a safe position. Additionally, it has the effect of indicating to the subject that delivery is completed. In use, therefore, the subject would apply device 110 to the skin, press downwards on the top surface 120 to begin delivery and shortly afterwards, top surface 120 would spring up indicating that delivery had been completed.
  • Fig. 21 there is indicated, generally at 130, a schematic illustration of a device according to the invention.
  • Device 130 is designed to be used in cases where a relatively long needle is required (more specifically where there is a high ratio of needle length to distance from hinge to penetration point.
  • Fig. 21 shows a device being used for intramuscular injections, and accordingly it employs a long delivery needle 131.
  • Delivery needle 131 must be sufficiently long to penetrate through the skin 132, fat 133 and into muscle 134 when base section 135 is applied to a subject and top surface 136 is pushed downwards so as to cause the penetration of the skin and the actuation of the expelling means.
  • the actual operation of the device can be the same as any of the devices previously illustrated, or can be a variant on these embodiments.
  • the hinge mechanism gives the needle's movement a lateral component (i.e. parallel to the surface of the skin). For a long needle or a relatively small device, this lateral movement of the needle between the position in which the point penetrates the surface of the skin and the position in which the needle is fully embedded can be substantial.
  • needle 131 of device 130 is provided with a curvature such that it lies along an arc of an imaginary circle 139.
  • the centre of circle 139 is at hinge 140, and the radius or of circle 139 is equal to the distance between hinge 140 and needle 131.
  • This curvature means that when needle 131 enters the skin, it does so at a single point and the entire needle enters the skin at the point where tip 137 penetrates the surface of the skin.
  • the application of device 130 is therefore far less traumatic than would be the case for a device having a straight needle, and after removal, the skin and underlying tissue is less damaged than would otherwise be the case.
  • This type of curved needle is not just required for intramuscular injections as even subcutaneous injections may require a delivery needle of up to 10 mm in length (depending on the site to which the device is being applied.
  • the device can be provided with a housing which will appeal to children and which they will readily apply to their skin (where they would be reluctant to do with a conventional injection device).

Abstract

A liquid drug delivery device is adapted to be adhered to the skin of a subject by a base member defining a skin-contacting surface having an adhesive coating. A columnar cartridge serves as reservoir for the drug and is incorporated in a housing which is connected to the base member such that in use the longitudinal axis of the cartridge is disposed substantially parallel to the skin-contacting surface. A delivery needle communicating in use with the interior of the cartridge penetrates the skin of the subject when the housing snaps downward relative to the base member. This action also causes the actuation of a citric acid/sodium bicarbonate gas generator which generates a gas to move a piston within the cartridge, compressing the drug compartment. This compression causes a stopper to be penetrated by a conduit in communication with the delivery needle, allowing the drug to be ejected from the compartment through the needle and into the subcutaneous tissue of the subject.

Description

Technical Field
This invention relates to devices for subcutaneous, intravenous, intramuscular or intradermal delivery of drugs to a subject.
Background Art
The conventional method of parenteral administration of a drug to a subject is by injection using a hypodermic syringe. A number of difficulties associated with these syringes have led to attempts to derive more advantageous drug delivery devices. Syringes are not generally advocated for use in self administration by patients because of the dangers of embolisms arising from the introduction of air bubbles into the bloodstream, incorrect dosing, and the accidental infection of third parties after use of the syringe. In any event, syringes cannot be used by children or by many elderly patients, and the use of syringes is very traumatic for the large number of people who are needlephobic to a greater or lesser extent.
In trying to provide improved syringes, a number of inventors have focussed on the provision of a pre-filled syringe or a pre-filled ampoule for use in a syringe, as these devices can be useful in addressing the problems of incorrect dosage or incorrect filling of syringes. Furthermore, some syringes have been provided with expelling means which automatically deliver the drug from the syringe body or ampoule, rather than relying on a conventional syringe mechanism which can be difficult to manipulate in a smooth uniform fashion with one hand. Examples of such devices are the syringe disclosed in U.S. Patent No. 2,390,246, the ampoule disclosed in U.S. Patent No. 2,445,477 and the disposable needleless hypodermic injector disclosed in U.S. Patent No. 3,527,212.
The devices of U.S. Patent Nos. 2,390,246 and 2,445,477 still require the patient to correctly administer the injection, which may be difficult for some patients, and which some patients may refuse to do because of a fear of needles. Furthermore, each of these documents discloses a very sophisticated and complex mechanical arrangement for activating the expelling means. The devices would, in consequence, be prohibitively difficult and expensive to mass produce and would be prone to failure due to device complexity.
The device of U.S. Patent No. 3,527,212 eliminates the use of needles and has a construction with fewer parts, but manufacture would still be difficult and expensive as the needleless injection of a drug requires the drug to be provided to the skin at pressures in excess of 400 lb/in2 (27.5 · 105 Pa). Thus, the device must be provided with a propellant at such a pressure when it is manufactured, and this pressure must be maintained throughout the shelf life of the device in a compartment which is bounded by a membrane strong enough to withstand the pressure but which is nevertheless easily rupturable by the manual depression of a plunger. Again, it will be appreciated that these requirements lead to a product which is quite difficult and expensive to manufacture.
Needleless devices have their own problems, since their correct use requires a certain degree of dexterity and strength. The device must be held firmly against the skin at the correct angle. Correct delivery of the drug requires it to be propelled at high pressure through the skin, so if the device is held at an incorrect angle or is not held firmly enough, then there is a strong likelihood that the medicament will not pass through the skin but will be dispersed into the air. As needleless injectors are usually quite bulky, the dexterity issue may be far from trivial from many patients.
Another limitation which is associated with each of the devices referred to above is that they can only be used for bolus administration, i.e. the immediate injection of a single entire dose. This is not suitable for all therapies, as it may be preferred in many cases to provide a continuous infusion of a drug both to avoid toxicity problems and to provide improved efficacy. Furthermore, if a drug is provided as a bolus injection, it may be necessary to inject a number of doses per day.
A number of infusion pumps are known, such as those described in U.S. Patent No. 4,886,499 and our own WO 95/13838. In general, however, infusion pumps are far more sophisticated and complex than syringes or syringe-based injectors, with the result that they are unable to compete commercially with conventional injectors.
The problems associated with complex devices should not be underestimated from a manufacturing point of view. Not only does it become increasingly difficult and expensive to mass-produce a device having large numbers of components, but the reliability of such devices is inherently worse. To illustrate this point, if each component in a production line is tested and found to have, on average, a reliability of 99% (1 failure in every 100), then devices having only 5 components can be predicted to have expected reliability rates of 95% (given by 0.995). Devices having 10, 20, and 50 of such components can be expected to have reliability rates of 90%, 82% and 61%, respectively. Evidently the safety implications of increasing device complexity cannot be ignored when considering drug delivery devices in particular.
U.S.-A-2 605 765 describes an automatic syringe for continuously and automatically administering medicinal compositions in fluid form to the body of a patient. The syringe comprises a housing provided with a variable volume chamber having a discharge passage leading to a hollow injection needle which extends approximately at right angles with respect to the bottom surface of the housing. During non-use of the syringe, the injection needle is protected by a removable cap. The fluid is expelled from the syringe by a power piston arrangement following removal of the protecting cap from the injection needle. Shortly before the device is applied, the power piston is primed for action.
Therefore, among the objects of the present invention are the provision of a drug delivery device which: is capable of delivering a pre-set dosage of drug to a subject; is suitable for use in self-administration by patients (including young patients and elderly patients); does not require the patient to consciously insert a needle into the skin; has a construction sufficiently simple to enable it to be mass produced at least as cheaply as (and in most cases more cheaply than) prior art bolus injectors described in the documents referred to above and substantially more cheaply than prior art infusion pumps; can provide either a bolus injection or can perform a continuous or controlled infusion; and overcomes the disadvantages associated with the conventional hypodermic syringe. Further objects and advantages of the invention will become apparent from the description given below.
Disclosure of Invention
Accordingly the invention provides a liquid drug delivery device comprising a base member defining a skin-contacting surface for application to the skin of a subject, a columnar cartridge serving as reservoir for the drug and which is connected to the base member such that in use the longitudinal axis of the cartridge is disposed substantially parallel to the skin-contacting surface, a delivery needle communicating in use with the interior of the cartridge and adapted to penetrate the skin of the subject, and means for expelling a drug out of the interior of the cartridge and through the skin of the subject via the delivery needle,
   characterised in that the connection between the cartridge and the base member allows relative movement therebetween from an initial configuration to a working configuration and is provided by a ginge enabling the cartridge and the base member to be pressed towards one another from a spaced-apart initial configuration to an adjacent working configuration.
Because the device has a skin-contacting surface and a columnar cartridge disposed substantially parallel thereto, the device can be applied to the skin in order to effect delivery of the drug. One can use a conventional columnar cartridge such as a refill cartridge of the type used in "pen-type" insulin injectors, or it can be any other type of columnar cartridge. Such cartridges may suitably be cylindrical glass or plastic cartridges, for example, and would preferably be extremely inexpensive to manufacture. The configuration of the device means it can be applied to the skin, and delivery can be effected in a single step application, as will be described below. The configuration which uses a skin-contacting surface and a delivery needle which penetrates the skin of the subject means that far less dexterity is required in administering the drug than is the case with many bolus injectors, including those referred -to previously.
The term "cartridge" as used herein denotes a columnar container or vessel for a liquid, preferably formed of glass or plastic. The term "cartridge" does not necessarily imply a component which is removable from the device as a whole, or a component which is replaceable, although the cartridge may in fact be removable or replaceable.
The term "liquid drug" includes drugs which are in the form of liquids, solutions, suspensions, or flowable gels.
Suitably, a portion of the interior of the cartridge defines a drug compartment for the drug, the drug being expelled from the compartment by a piston actuated by the expelling means.
It will be appreciated that when a piston is employed to expel the drug the columnar cartridge may be cylindrical or it may be of generally cylindrical form (the cross section need not be circular). Indeed, one can envisage cases where a cylinder having a slight longitudinal curve would be employed for design reasons. Such cartridge shapes are perfectly acceptable provided of course that the piston is still effective to expel the drug from the drug compartment.
Preferably, the interior of the cartridge also defines a chamber housing the expelling means, such that the actuation of the piston by the expelling means causes the expansion of said chamber and the contraction of said drug compartment.
This arrangement is advantageous because the cartridge (which may be as simple as a glass or plastic cylinder) can house both the drug and the expelling means. Indeed, a number of embodiments described in detail below illustrate this arrangement. By incorporating the expelling means into the cartridge, one obtains significant savings in space, thereby making the device as small and unobtrusive as possible. This is particularly important if the device is to be worn for an extended period of time.
One can also envisage embodiments in which the expelling means is incorporated within the cartridge but the chamber containing the expelling means is in fact also the drug compartment and the expelling means serve to pull the piston and contract the chamber (and drug compartment). There are practical disadvantages associated with this arrangement given that the expelling means must be sterile and inert if it is in contact with the drug. For practical purposes it is preferable to use the piston to separate an expansible chamber for the expelling means and a contractible drug compartment for the drug.
Suitably, the device is provided with a conduit enabling fluid communication to be established in use between the drug compartment and the delivery needle.
Preferably, the conduit extends at substantially right angles from the delivery needle.
By having a delivery needle having a conduit extending at substantially right angles from the delivery needle, the conduit can access the drug compartment through an end of the cartridge (in a direction purposely parallel to the skin-contacting surface), and the delivery needle can deliver drug passing out of the drug compartment through the conduit by penetrating normally through the skin. Clearly, an angle of exactly 90° is not required (although it may be preferred), but one would envisage that the conduit extends from the delivery needle at 80-100°, preferably 85-95° (and most preferably 90°). This allows the needle to penetrate the skin vertically and simultaneously allows communication to be established between this delivery needle and a cartridge lying exactly parallel to the skin.
Preferably, the conduit is integral with the delivery needle.
Suitably, the delivery needle and the conduit form part of a needle assembly mounted on an end of the cartridge.
In preferred embodiments, the device further comprises a mechanism for actuating the expelling means.
As indicated above the connection between the cartridge and the base member allows relative movement therebetween from an initial configuration to a working configuration.
Preferably, said relative movement operates the mechanism for actuating the expelling means.
In other words, the device can be in an initial configuration in which it is maintained during storage or before use, and then by moving the cartridge and base member relative to one another, the device is primed for use and the expelling means is actuated.
Further, preferably, said relative movement causes the delivery needle to project through the plane of the skin-contacting surface and thereby penetrate the skin in use.
This arrangement allows the skin-contacting surface to be placed on the skin (this surface being suitably provided with an adhesive coating or the device being provided with some other means of retaining the skin-contacting surface on the skin), and then a relative movement between the base member and the cartridge causes the penetration of the skin (and optionally, the actuation of the expelling means).
Further, preferably, said relative movement causes the establishment of fluid communication between the drug compartment and the delivery needle.
If the relative movement between the cartridge and base member accomplishes all three preferred acts, namely the actuation of the expelling means, the penetration of the skin by the delivery needle and the establishment of fluid communication between the drug compartment and the delivery needle, then one can achieve a single-step application of the device, whereby some movement between the cartridge and the base member achieves the delivery of drug in a safe and predictable manner. The relative movement may be rotational or translational. For example, the cartridge could be incorporated in a first section of a housing which is screwed relative to a second section of the housing (the second section incorporating the base member), with this screwing movement initiating delivery.
Suitably, the skin-contacting surface is provided with an aperture through which the delivery needle extends in use.
If the cartridge is movable relative to the base member, the needle can be retracted in the initial configuration and it can extend through the skin-contacting surface in the working configuration; this allows for a device in which the needle is never seen by the subject in normal use. This is particularly suitable for needlephobics or people who, while not actually needlephobic, are upset to a greater or lesser degree by needles and injections.
Preferably, an end of the cartridge is provided with a stopper and the conduit and stopper are movable relative to one another to allow the conduit to penetrate through the stopper and thereby establish said communication.
The conduit can be pointed or blunt, provided that it is able to penetrate through and establish communication with the interior of the cartridge.
This arrangement is advantageous because it allows the contents of the drug compartment to be maintained in a sterile condition until the moment when communication is established between the delivery needle and the drug compartment. As described above, and as further described in detail below, the device can be applied to the skin and a -single action can cause establishment of communication between the delivery needle and the cartridge at roughly the same moment as the delivery needle penetrates the skin. Thus, sterility is ensured from the point of view of the patient. The skin-contacting surface may be covered before use by a release liner of some sort.
According to one embodiment, the position of the needle assembly is fixed with respect to the cartridge, and the stopper is movable relative to both the cartridge and the needle assembly.
Suitably, the actuation of the expelling means causes the stopper to be pressed onto and penetrated by the conduit.
According to another embodiment, the position of the stopper is fixed with respect to the cartridge, and the needle assembly is movable relative to both the cartridge and the stopper.
In certain embodiments, the expelling means comprises a pre-compressed spring.
Preferably, the mechanism for actuating the expelling means comprises a catch which when released enables the pre-compressed spring to relax.
Most preferably, a relative movement between the cartridge and the base member from an initial configuration to a working configuration causes the catch to be released.
Alternatively, the expelling means comprises a gas generator which generates a gas when two or more reactants are brought into contact.
Suitably, the gas generator comprises at least one liquid.
Advantageously, the gas generator comprises the components of an effervescent couple.
Again, alternatively, the expelling means comprises a material which swells in the presence of a liquid, and also comprises a supply of said liquid.
Suitably, in such cases, said material is a swellable gel and said liquid is water.
Suitably, in embodiments where the expelling means comprises a liquid as an essential component, and when the cartridge and base member are movable relative to one another as described above, said liquid is contained within a rupturable compartment and the mechanism for actuating the expelling means comprises a penetrating member, the penetrating member and the rupturable compartment being moved relative to one another upon the relative movement of the cartridge and the base member , so as to cause the penetration of said rupturable compartment and the actuation of the expelling means.
Suitably, the device further comprises a snap mechanism which maintains a stable initial configuration and a stable working configuration and which when actuated causes the device to snap from said initial configuration to said working configuration.
Further, suitably, the device is provided with resilient means biasing the device to said initial configuration and means for disengaging said snap mechanism when delivery has been completed.
Preferably, said disengaging means comprises a member linked to said piston such that when the piston has completed the expulsion of drug from the drug compartment, said member is caused to move and said movement causes the disengagement of said snap mechanism, such that said resilient means causes the device to resume said initial configuration.
Thus, if the device is provided with both a snap mechanism and a spring biasing the device to the initial configuration, the automatic release of the snap mechanism after completion of delivery causes the spring to return the device to the initial configuration (being no longer held in the working configuration by the snap mechanism). Suitably, this movement will cause the retraction of the delivery needle from the skin, optionally to a point where it is no longer visible.
This action (which might be observed by the cartridge snapping away from the base member) informs the subject that delivery has been completed and, in certain cases, retracts the needle to the point where it is concealed from the subject both before use and after use.
Suitably, said relative movement is a pivotal movement.
According to a further embodiment, said delivery needle projects through the plane of the skin-contacting surface at or outside of the periphery of the skin-contacting surface.
It is preferred if the delivery needle projects through the plane at a point on the periphery of the skin-contacting surface distal from the hinge, as this means that the needle will jab through the skin more quickly than it would if it was located right beside the hinge. The quicker the needle pierces the skin the less painful it is likely to be for the subject.
According to one embodiment, the delivery needle is in the shape of a segment of arc of an imaginary circle, said circle having a radius equal to the distance between the delivery needle and the hinge and lying in a plane which is substantially normal to the plane of the skin-contacting surface.
This embodiment with a curved needle is useful where the needle is unusually long, as a pivotal movement such as that provided by a hinge causes the needle to have a lateral component of velocity when it is penetrating the skin. This lateral movement of the needle causes the stretching or tearing of the skin in extreme cases, and in any event leaves a bigger entry wound than would otherwise be the case. The dimensions of the imaginary circle given above ensure that the body of the needle exactly follows the point of the needle on its path into the subject.
Alternatively, the delivery needle may be straight. This is preferred in embodiments in which delivery needle moves straight down into the skin, or in embodiments where the length of the delivery needle or the radius of the imaginary circle means that the needle has a negligibly small lateral component of movement upon entering the so skin that it would be uneconomical or unnecessary to make a curved needle. Indeed, in many cases, it will be unnecessary for the needle to be curved.
Typical medicaments suitable for use with the device according to the invention include peptides, proteins or hormones such as insulin, calcitonin, calcitonin gene regulating protein, atrial natriuretic protein colony stimulating factor, betaseron, erythropoietin (EPO), interferons such as a, b or g interferon, somatropin, somatotropin, somatostatin, insulin-like growth factor (somatomedins), luteinizing hormone release hormone (LHRH), tissue plasminogen activator (TPA), growth hormone releasing hormone (GHRH), oxytocin, estradiol, growth hormones, leuprolide acetate, factor VIII, interleukins such as interleukin-2, and analogues thereof; analgesics such as fentanyl, sufentanil, butorphanol, buprenorphine, levorphanol, morphine, hydromorphone, hydrocodone, oxymorphone, methodone, lidocaine, bupivacaine, diclofenac, naproxen, paverin, and analogues thereof; anti-migraine agents such as sumatriptan, ergot alkaloids, and analogues thereof; anti-coagulant agents such as heparin, hirudin, and analogues thereof; anti-emetic agents such as scopolamine, ondanesetron, domperidone, metoclopramide, and analogues thereof; cardiovascular agents, anti-hypertensive agents and vasodilators such as diltiazem, clonidine, nifedipine, verapamil, isosorbide-5-mononitrate, organic nitrates, agents used in the treatment of heart disorders, and analogues thereof; sedatives such as benzodiazepines, phenothiozines, and analogues thereof; narcotic antagonists such as naltrexone, naloxone, and analogues thereof; chelating agents such as deferoxamine, and analogues thereof; anti-diuretic agents such as desmopressin, vasopressin, and analogues thereof; anti-anginal agents such as nitroglycerine, and analogues thereof; anti-neoplastics such as 5-fluorouracil, bleomycin, and analogues thereof; prostaglandins and analogues thereof; chemotherapy agents such as vincristine, and analogues thereof; and antisense oligonucleotides.
Brief Description of the Drawings
The invention will now be further described by the following descriptions of embodiment thereof, given by way of example only, with reference to the accompanying Drawings, in which:
  • Fig. 1 is a sectional elevation of a cartridge-based drug delivery device according to the invention, before use;
  • Fig. 2 is a section elevation of the device of Fig. 1, in use;
  • Fig. 3 is a perspective view of the device as illustrated in Fig. 1;
  • Fig. 4 is a sectional elevation of a second embodiment of a device according to the invention, before use;
  • Fig. 5 is a perspective view of the device of Fig. 4;
  • Fig. 6 is a sectional elevation of a third embodiment of a device according to the invention, before use;
  • Fig. 7 is a sectional elevation showing the device of Fig. 6 when it has been primed and is ready for use;
  • Fig. 8 is a sectional elevation of the device of Figs. 6 and 7, when delivery has been completed;
  • Figs. 9-11 are perspective views of the device as illustrated in Figs. 6-8, respectively;
  • Fig. 12 is a section elevation of an alternative expelling means for use in a device according to the invention;
  • Figs. 13-15 are schematic representations of a fourth embodiment of the device in successive stages of being applied to the skin of a subject;
  • Fig. 16 is a sectional elevation of a fifth embodiment of a device according to the invention, illustrated before use;
  • Fig. 17 is a sectional elevation of the device of Fig. 16, when delivery has almost been completed;
  • Fig. 18 is a cross-sectional elevation of the device of Fig. 17, taken along the line A-A;
  • Fig. 19 is an enlarged view of a detail of Fig. 18;
  • Fig. 20 illustrates the device of Figs. 16-19, after use; and
  • Fig. 21 is a schematic representation of a sixth embodiment of a device according to the invention.
  • Modes for Carrying Out the Invention
    In Fig. 1 there is indicated, generally at 10, a cartridge-based drug delivery device according to the invention. Device 10 is in the form of a body 11 comprising a cartridge 12 and a member 13 defining a skin contacting surface 14. Surface 14 is covered by a release liner 15 before use.
    A piston 16 is contained in cartridge 12 and defines on one side thereof a drug compartment 17 and on the other side thereof a driving chamber 18. Compartment 17 is filled with a liquid drug and is sealed at the end opposite piston 16 by a stopper 19. A needle assembly 20 is mounted on cartridge 12. Needle assembly 20 has a hollow delivery needle 21 extending therefrom, and delivery needle 21 is provided with communication means in the form of a conduit needle 22. As illustrated in Fig. 1, conduit needle 22 penetrates into but not through stopper 19 before use.
    A spring 23 is held under compressed tension by a rod 24 having a plate 25 at one end thereof and a catch projection 26 at the other end thereof. Rod 24 extends through an orifice 26a in a wall section 27 and catch projection 26 is retained by wall section 27 such that spring 23 is held under tension as long as catch projection 26 remains in position. Plate 25 abuts against piston 16.
    Cartridge 12 is connected to member 13 by means of a living hinge 28. A simple snap mechanism (not shown) causes device 10 to remain in the configuration illustrated in Fig. 1 until cartridge 12 and member 13 are compressed together giving rise to the working configuration illustrated in Fig. 2. An aperture 29 in skin-contacting surface 14 allows needle 21 to project therethrough, thereby permitting cartridge 12 and member 13 to be pressed together such that, in use, cartridge 12 lies substantially flat against skin-contacting surface 14.
    The operation of the device can be explained as follows. Before use, the device is in the configuration shown in Fig. 1. Fig. 3 shows a perspective view of device 10 in the same configuration, in which body 11, cartridge 12, member 13, release liner 15, piston 16, needle assembly 20 and aperture 29 can be seen. Immediately before use, release liner 15 is peeled away from skin-contacting surface 14, and skin contacting surface 14 is then placed against the skin to which it adheres by means of an adhesive coating. Downward pressure is then exerted on the upper surface 30 (see Fig. 3) of body 11 causing cartridge 12 to be snapped towards member 13 by means of hinge 28 and the snap mechanism (not shown). Delivery needle 21 passes through aperture 29 and penetrates through the skin.
    It can be seen in Fig. 1 that catch projection 26 rests against an abutment 31 before use. Referring to Fig. 2, it can be seen that when cartridge 12 has been snapped towards skin contacting surface 14, wall section 27 moves relative to abutment 31. Because wall section 27 moves downwards and catch projection 26 is prevented from moving downwards by abutment 31, the relative movements of wall section 27 and catch projection 26 cause catch projection 26 to be dislodged enabling it to pass through orifice 26a in wall section 27, which it does readily as spring 23 is under compressed tension. Once catch projection 26 is released, spring 23 urges rod 24 to move towards the position shown in Fig. 2.
    This movement of rod 24 causes plate 25 to push piston 16 so as to compress drug compartment 17. As the liquid filling compartment 17 is incompressible, the pressure is transmitted to stopper 19 which moves towards needle assembly 20 such that conduit needle 22 penetrates completely through stopper 19, thereby effecting communication between compartment 17 and delivery needle 21. This creates an outlet from compartment 17 (namely via the delivery needle 21 into the skin, subcutaneous tissue or cardiovascular system of the subject to whom the drug is being delivered), thereby permitting piston 16 to continue to move forward under the urging of spring 23 (via plate 25), which causes the contraction of compartment 17 and the ejection of the liquid drug therefrom. Piston 16 moves forward until it meets stopper 19, at which point the reservoir is effectively empty and the device can be removed from the skin.
    Removal of the device from the skin merely involves pulling body 11 upwards to remove delivery needle 21 from the skin, and peeling skin contacting surface 14 away from the skin. The use of a snap mechanism means that cartridge 12 and member 13 disengage from one another (i.e. body 11 snaps back to its original configuration as illustrated in Figs. 1 and 3) before skin contacting surface 14 is peeled off the skin. This disengagement has the result that when removed, device 10 is harmless because delivery needle 21 has been retracted through aperture 29 and is thereby concealed, preventing accidental injury and possible risk of infection from delivery needle 21.
    While the description of operation given above details the operation of the mechanism at some length, the actual operation from the patient's point of view is as follows. Firstly, the release liner is peeled away to reveal a sterile adhesive surface. Secondly, the device is pressed against the skin by applying pressure to top surface 30. This act causes (i) the adhesion of skin contacting surface 14, (ii) the snapping together of cartridge 12 and member 13, (iii) the resulting dislodgement of catch projection 26, which leads to (iv) the penetration of stopper 19 by conduit needle 22 and (v) the delivery of the contents of compartment 17 through delivery needle 21. After delivery, body 11 is lifted away from the skin. This act causes the retraction of needle 21, thereby making the device safe for disposal.
    All the patient has to do, therefore, is: (a) peel away the release liner, (b) press the device against the skin, and (c) lift the device off the skin when delivery has been completed. The completion of delivery can be observed by monitoring the movement of piston 16 along the length of cartridge 12 (see Fig. 3).
    All of the steps relating to correctly administering a precise dosage of drug are accomplished by the single step (b), namely applying pressure to upper surface 30. This simplicity opens up the possibility of self administration by patients who would be unable or unwilling to self administer a drug otherwise. The configuration of device 10 not only ensures that the entire mechanism is activated by a single step, but it also compels the patient to administer the drug correctly. The mechanism causes delivery needle 21 to penetrate the skin at the correct angle and to the correct depth, and since cartridge 12 is prefilled with a known volume of drug, the metering of the dose to be delivered is automatic and is removed from the patient's responsibility.
    Furthermore, while other drug delivery devices are known which can be applied to the skin such that a needle correctly penetrates the skin and such that the drug is delivered upon application of the device, the structure and mode of operation of the device shown in Figs. 1-3 is much simpler than for known devices. Manufacturing costs are significantly lowered, and the risks of malfunction or patient error are clearly reduced by simplifying the construction and operation of the device.
    A further advantage provided by the device of Figs. 1-3 is that from the patient's point of view, the needle is invisible. This is a distinct advantage for subjects who are uncomfortable with the idea of injections and needles. The diameter of the needle used in the embodiment of Figs. 1-3 is 0.25 mm, making it sufficiently small that it is effectively painless when it penetrates the skin. The internal diameter is nevertheless big enough to allow the delivery of macromolecular compounds such as peptides, polypeptides and proteins. Although device 10 as shown in Figs. 1-3 does not entirely conceal delivery needle 21 (which can be seen by looking into the gap between member 13 and cartridge 12), a collar can be provided around the periphery of skin contacting surface 14 so as to conceal the needle at all times, if the visibility of the needle is a major concern.
    Referring now to Fig. 4, there is indicated, generally at 40, a different embodiment of a drug delivery device according to the invention. Device 40 is in many respects similar to device 10 of Figs. 1-3, but a different expelling means is employed and a different mechanism for actuating the expelling means is employed. In device 40, piston 41 is driven by gas pressure. Gas is generated by the reaction of a quantity of citric acid solution 42 with a sodium bicarbonate tablet 43. In Fig. 4, device 40 is illustrated before use (a perspective view can be seen in Fig. 5). Citric acid solution 42 is contained within a compartment defined by a rupturable membrane 44. A solid needle 45 is disposed with its point immediately adjacent to membrane 44. Needle 45 projects from a wishbone structure 46 through a stopper 47. Stopper 47 and piston 41 form a sealed compartment such that the generation of gas causes piston 41 to move in the direction indicated by the arrow.
    The gas generator 42,43,44 is actuated by pressing the cartridge 48 and member 49 (which defines a skin-contacting surface 50) together. In practice this is done by placing surface 50 against the skin and pressing downwards on upper surface 51 (see Fig. 5). When cartridge 48 and member 49 are pressed together (via the flexing of a hinge 52) a pair of brackets 53 supporting wishbone structure 46 also approach one another. Wishbone structure 46 is flexible, so the movement of the brackets 53 causes wishbone structure 46 to flex, thereby moving needle 45 in the direction indicated by the arrow. This movement ruptures membrane 44, thereby releasing citric acid 42 which contacts sodium bicarbonate 43 and generates a gas to provide a driving force equivalent to spring 23 of device 10 illustrated in Figs. 1-3.
    Referring now to Figs. 6-11, one can see a further embodiment of the invention. Figs. 6, 7 and 8 illustrate the device in sectional elevation, and Figs. 9, 10 and 11 are perspective views of the device as illustrated in Figs. 6, 7 and 8, respectively.
    Referring first to Fig. 6, the device, indicated generally at 60 has many features in common with the devices previously described. In particular, there is a cartridge 61 connected by a hinge 62 to a member 63 defining an adhesive skin-contacting surface 64. A piston 65 defines a drug compartment 66 which is sealed by a stopper 67.
    A needle assembly 68 is moveable with respect to cartridge 61 in the direction indicated by the arrow so as to pierce stopper 67 and thereby provide communication between drug compartment 66 and a delivery needle 69, as illustrated in Fig. 7.
    Pressure in the direction indicated by the arrow also causes cartridge 61 to move relative to a mounting member 70 on which cartridge 61 is slidably mounted. Member 70 is provided with penetrating means 71. When cartridge 61 moves in the direction indicated by the arrow relative to member 70, penetrating means 71 pierces a compartment 72 to release a quantity of water.
    Referring to Fig. 7, it can be seen that a perforated polyethylene bellows 73 is wetted by the water released from compartment 72. Bellows 73 is water permeable and is filled with a gel which swells in the presence of water, such as acrylite gels. The choice of gel material determines to a large extent the rate of delivery. The delivery rate is also affected by the permeability of the bellows. The permeability of the bellows may be determined by the number and size of perforations or by the nature of the material (which may be water permeable) used for the bellows.
    When needle assembly 68 has been pushed back to the extent indicated in Figs. 7 and 10, the device is primed, at which point the release liner 74 is peeled away, skin-contacting surface 64 is pressed against the skin, and then pressure is applied to upper surface 75 (Figs. 8 and 11) such that delivery needle 69 emerges through aperture 76 and penetrates the skin of the subject. Delivery is effected by the expansion of bellows 73 (when wetted) to drive piston 65 (see Fig. 8).
    The device of Figs. 6-11 is not shown to scale as the degree of expansion shown in Fig. 8 would not be achieved by a bellows and water compartment of the size shown in Figs. 6 and 7. However, the principle of a permeable, gel-filled bellows expanding as water is absorbed by the gel is clear.
    A freely permeable barrier 77 is provided between mounting member 70 and bellows 73. Barrier 77 is fixed relative to the cartridge, and so when compartment 72 is pierced and bellows 73 begins to expand as it absorbs water, barrier 77 prevents bellows 73 from expanding backwards into the space formerly occupied by the water in compartment 72. Although cartridge 61 is firmly mounted on mounting member 70, the seal between cartridge 61 and mounting member 70 is vacuum tied. A small amount of leakage is allowed for, to allow air to be drawn into the space between mounting member 70 and barrier 77 as the water is drawn out of that space by absorption into bellows 73. The degree of leakage is small enough, however, to prevent water from seeping out (this is perfectly possible given the differences in properties between water and air). As an alternative, a gas-permeable, water impermeable material could be used for mounting member 70 (or a section thereof).
    An important difference between the devices of Figs. 1-5 on the one hand and the device of Figs. 6-11 on the other hand is that whereas spring 23 (in Figs. 1-3) relaxes rapidly to provide a bolus delivery of drug, and gas generator 42,43,44 (in Figs. 4 and 5), when actuated, generates a gas quickly over a short period of time to give bolus delivery, the swelling gel mechanism of Figs. 6-11 provides a slow continuous expansion. Accordingly, whereas device 10 of Figs. 1-3 and device 40 of Figs. 4 and 5 act as bolus injectors, device 60 of Figs. 6-11 acts as an infusion pump which can be used to deliver drug over a period dictated by the design of the device. It generally delivers all of the drug over an extended period of time, equivalent to the delivery provided by an infusion pump (for example, such as over a 12 hour, 24 hour or 48 hour period).
    Referring next to Fig. 12, a further expelling means is indicated, generally at 80. Expelling means 80 is again positioned at an end of a cartridge 81. The expelling means 80 consists essentially of a fixed end cap 82 and a moveable end cap 83 which is slidable within cartridge 81 and which serves as a piston to compress drug compartment 84. Between them, the end caps 82,83 define a driving chamber which is filled with a swellable gel 85. A flexible perforated spiral wound plastics tube 86 also extends within the space defined by the end caps 82,83, and tube 86 is in communication, in use, with a source of water (not shown) via an inlet 87 in end cap 82. When water enters tube 86, it is free to enter gel 85 via perforation is in tube 86. Gel 85 expands when it absorbs the water and because gel 85 continues to absorb water as it expands, water is continually drawn in via inlet 87. The expansion of gel 85 causes end cap 83 to slide within the interior of cartridge 81 thereby compressing drug compartment 84 and ejecting a liquid drug contained therein through an outlet, as described in relation to previous embodiments.
    Figs. 13-15 illustrate a schematic diagram of a further embodiment of the invention. It will be noted that the device indicated generally at 90 has many features in common with devices previously described. In particular, there is a cartridge 91 slidably mounted on a mounting member 92 provided with penetrating means 93. A piston 94 defines a drug compartment 95 on one side thereof and a driving chamber 96 on the other side thereof. Driving chamber 96 contains a rupturable citric acid compartment 97 and a sodium bicarbonate tablet 98 such that when compartment 97 is penetrated by penetrating means 93, citric acid is released to sodium bicarbonate tablet 98 in order to generate a gas and drive piston 94 along cartridge 91.
    The end of drug compartment 95 opposite piston 94 is sealed by a penetrable stopper 99. A needle assembly 100 which has a hollow conduit needle 101 extending at right angles from a hollow delivery needle 102 is mounted on cartridge 91 such that movement of needle assembly 100 in the direction indicated by the arrow causes conduit needle 101 to pierce stopper 99, thereby establishing communication between drug compartment 95 and delivery needle 102.
    Mounting member 92 is connected by a hinge to a base member 103 which defines a skin-contacting surface 104. Base member 103 is provided with a lever mounting 105 on which a lever 106 is pivotally mounted. Actuation of lever 106 in the direction indicated by the arrow in Fig. 13 causes the device to assume the configurations shown in Fig. 14 (initially) and Fig. 15 (subsequently). Actuation of lever 106 pushes needle assembly 100 (to which lever 106 is pivotally mounted by means of a pivot 107) onto cartridge 91, and pushes cartridge 91 onto mounting member 92. This causes (a) the penetration of stopper 99 by conduit needle 101 and (b) the penetration of citric acid compartment 97 by penetrating means 93. As indicated in relation to previous embodiments, this has the effect of establishing communication between drug compartment 95 and delivery needle 102 and also of initiating the generation of gas which will drive piston 94 to expel the liquid drug from drug compartment 95.
    Continued actuation of lever 106 to the position indicated in Fig. 15 causes needle 102 to penetrate into the skin. It will be appreciated that the actuation of lever 106 accomplishes the actuation of the expelling means, the establishment of communication between the drug compartment 95 and the delivery needle 102, and the correct penetration angle and depth of delivery needle 102 into the skin. Correct and fail-safe dosing is therefore inevitable.
    In Fig. 16 there is indicated, generally at 110 a device similar to that of Fig. 1. Thus, it will be noted that the main components are identical and that the expelling means which drives the piston 111 along cartridge 112 comprises the spring 113 which acts on pusher plate 114 to drive the piston 111. Before use, the spring 113 is held in place by rod 115 and catch projection 116 which extends through an orifice 117 in wall section 118.
    As with the device of Fig. 1, when base member 119 is placed on and adheres to the skin and pressure is exerted on top surface 120 of device 110, catch projection 116 moves relative to orifice 117 because catch projection 116 is prevented from moving downwards by abutment 121. Precompressed spring 113 causes catch projection 116 to move through orifice 117 and exerts a force on piston 111. As previously described in relation to the device of Figs. 1-3, this force causes a stopper 122 to pierce conduit needle 122a and then causes the ejection of drug from the interior of cartridge 112.
    Referring initially to Fig. 17, it can be seen that rod 115 is provided with first and second extension members 123, 124. As rod 115 moves from the starting position illustrated in Fig. 16 towards the position illustrated in Fig. 17, catch projection 116 serves to pull first extension member 123 forward and this in turn pulls the second extension member 124 forward. The second extension member 124 is provided with a projection 125 which extends through an orifice 126 in abutment 121. Projection 125 and orifice 126 act as a snap mechanism which is illustrated in greater detail in Figs. 18 and 19. Fig. 18 shows a sectional elevation through the line A-A in Fig. 17. In Fig. 18 abutment 121, projection 125 and orifice 126 can been seen. Fig. 19 shows projection 125 and orifice 126 in greater detail. It can be seen that orifice 126 is provided with a pair of resilient teeth 127. These teeth allow projection 125 to move from the initial position as shown in Fig. 16 (and indicated in dotted outline in Fig. 19 by reference numeral 125') to the working position shown in Fig. 17 (indicated by reference numeral 125 in Fig. 19). When device 110 is applied to the skin and top surface 120 is pressed downwards, projection 125 snaps from position 125' to the position shown in Fig. 19. A spring 128 (see Figs. 16 and 17) resists this downward movement. However, once projection 125 has snapped downwards, resilient teeth 127 prevent projection 125 from moving back up under the urging of spring 128.
    If one refers to Fig. 20, it can be seen that when piston 111 moves to its final position, catch projection 116 pulls first extension member 123 and second extension member 124 forwards to a sufficient extent that projection 125 is pulled forward and dislodged from orifice 126. This disengages the snap mechanism and allows cartridge 112 to move away from base member 119 under the influence of spring 128, to the position illustrated in Fig. 20. This has the effect of disengaging the delivery needle 129 from the skin and retracting it to a safe position. Additionally, it has the effect of indicating to the subject that delivery is completed. In use, therefore, the subject would apply device 110 to the skin, press downwards on the top surface 120 to begin delivery and shortly afterwards, top surface 120 would spring up indicating that delivery had been completed.
    The same or a similar snap mechanism could be used with many of the other embodiments previously illustrated, as will be apparent to the skilled person.
    In Fig. 21 there is indicated, generally at 130, a schematic illustration of a device according to the invention. Device 130 is designed to be used in cases where a relatively long needle is required (more specifically where there is a high ratio of needle length to distance from hinge to penetration point. For example, Fig. 21 shows a device being used for intramuscular injections, and accordingly it employs a long delivery needle 131.
    Delivery needle 131 must be sufficiently long to penetrate through the skin 132, fat 133 and into muscle 134 when base section 135 is applied to a subject and top surface 136 is pushed downwards so as to cause the penetration of the skin and the actuation of the expelling means. The actual operation of the device can be the same as any of the devices previously illustrated, or can be a variant on these embodiments.
    The important point to note about device 130 is that the length of needle 131 (exaggerated) causes its own problems. If needle 131 was straight, the point 137 thereof would pierce the skin and then as cartridge 138 approached base section 135, the remainder of the needle would follow the point into the skin. However, as well as entering the skin vertically (i.e. normal to the surface of the skin), the hinge mechanism gives the needle's movement a lateral component (i.e. parallel to the surface of the skin). For a long needle or a relatively small device, this lateral movement of the needle between the position in which the point penetrates the surface of the skin and the position in which the needle is fully embedded can be substantial. Instead of creating a single entry point, the needle causes the skin to stretch or tear during penetration and retraction of the needle. However, needle 131 of device 130 is provided with a curvature such that it lies along an arc of an imaginary circle 139. The centre of circle 139 is at hinge 140, and the radius or of circle 139 is equal to the distance between hinge 140 and needle 131. This curvature means that when needle 131 enters the skin, it does so at a single point and the entire needle enters the skin at the point where tip 137 penetrates the surface of the skin. The application of device 130 is therefore far less traumatic than would be the case for a device having a straight needle, and after removal, the skin and underlying tissue is less damaged than would otherwise be the case.
    This type of curved needle is not just required for intramuscular injections as even subcutaneous injections may require a delivery needle of up to 10 mm in length (depending on the site to which the device is being applied.
    Of course, it might be thought that the lateral movement of the needle could be reduced to a negligible amount by providing the needle closer to the hinge, and this is undoubtedly true. However, it has been found that it is advantageous to locate the needle at a point distal from the hinge as this means that when the cartridge moves towards the base member (particularly when a snap mechanism is provided) the velocity of the needle into the skin is much higher and the application of the device is, as a result, less painful.
    Another reason why the needle cannot simply be placed close to the hinge in order to overcome the problems associated with lateral movement during penetration is because this places constraints on the angle of rotation between the cartridge and the skin contacting surface (e.g. in moving from the configuration of Fig. 1 to the configuration of Fig. 2). Conversely, when the needle is positioned adjacent to the hinge point, even a relatively large angle of rotation gives a limited penetration depth. For reasons of compactness during storage and transit, it is usually preferred to keep the open angle at the hinge to a minimum, i.e. to keep the device as flat as possible.
    As an aid to compliance for children, the device can be provided with a housing which will appeal to children and which they will readily apply to their skin (where they would be reluctant to do with a conventional injection device).

    Claims (33)

    1. A liquid drug delivery device (10; 40; 60; 90; 110; 130) comprising a base member (13; 49; 63; 103; 119; 135) defining a skin-contacting surface (14; 50; 64; 104) for application to the skin of a subject, a columnar cartridge (12; 48; 61; 81; 91; 112) serving as reservoir (17; 66; 84; 95) for the drug and which is connected to the base member (13; 49; 63; 103; 119; 135) such that in use the longitudinal axis of the cartridge (12; 48; 61; 81; 91; 112) is disposed substantially parallel to the skin-contacting surface (14; 50; 64; 104), a delivery needle (21; 69; 102; 129; 131) communicating in use with the interior of the cartridge (12; 48; 61; 81; 91; 112) and adapted to penetrate the skin of the subject, and means (23, 24; 42, 43, 44; 72, 73; 85; 97, 98; 113, 114) for expelling a drug out of the interior of the cartridge (12; 48; 61; 81; 91; 112) and through the skin of the subject via the delivery needle (21; 69; 102; 129; 131), characterised in that the connection between the cartridge (12; 48; 61; 81; 91; 112) and the base member (13; 49; 63; 103; 119; 135) allows relative movement therebetween from an initial configuration to a working configuration and is provided by a hinge (28; 52; 62; 140) enabling the cartridge (12; 48; 61; 91; 112) and the base member (13; 49; 63; 103; 119; 135) to be pressed towards one another from a spaced-apart initial configuration to an adjacent working configuration.
    2. A device according to Claim 1, wherein a portion of the interior of the cartridge (12; 48; 61; 81; 91; 112) defines a drug compartment (17; 66; 84; 95) for the drug, the drug being expelled from the compartment (17; 66; 84; 95) by a piston (16; 41; 65; 83; 94; 111) actuated by the expelling means (23, 24; 42, 43, 44; 72, 73; 85; 93, 97, 98; 113, 114).
    3. A device according to Claim 2, wherein the interior of the cartridge (12; 48; 61; 81; 91; 112) also defines a chamber (18; 82, 83; 96) housing the expelling means (23, 24; 42, 43, 44; 72, 73; 85; 97, 98) such that the actuation of the piston (16; 41; 65; 83; 94) by the expelling means (23, 24; 42, 43, 44; 72; 73; 85; 97, 98) causes the expansion of said chamber (18; 82, 83; 96) and the contraction of said drug compartment (17; 66; 84; 95).
    4. A device according to Claim 2 or 3, which is provided with a conduit (22; 101; 122a) enabling fluid communication to be established in use between the drug compartment (17; 66; 84; 95) and the delivery needle (21; 69; 102; 129).
    5. A device according to Claim 4, wherein the conduit (22; 101; 122a) extends at substantially right angles from the delivery needle (21; 69; 102; 129)
    6. A device according to Claim 5, wherein the conduit (22; 101; 122a) is integral with the delivery needle (21; 69; 102; 129).
    7. A device according to Claim 5 or 6, wherein the delivery needle (21; 69; 102; 129) and the conduit (22; 101; 122a) form part of a needle assembly (20; 68; 100) mounted on an end of the cartridge (12; 48; 61; 81; 91; 112).
    8. A device according to any preceding claim, further comprising a mechanism (26, 27, 31; 45, 46; 71; 86; 93; 115, 116) for actuating the expelling means (23, 24; 42, 43, 44; 72, 73; 85; 97, 98; 113, 114).
    9. A device according to any one of Claims 1-8, wherein said relative movement operates the mechanism (26, 27; 31; 45, 46; 71; 93; 115, 116) for actuating the expelling means (23, 24; 42, 43, 44; 72, 73; 97; 98; 113, 114).
    10. A device according to Claim 9, wherein said relative movement causes the delivery needle (21; 69; 102; 129) to project through the plane of the skin-contacting surface (14; 50; 64; 104) and thereby penetrate the skin in use.
    11. A device according to Claim 9 or 10, wherein said relative movement causes the establishment of fluid communication between the drug compartment (17; 66; 95) and the delivery needle (21; 69; 102).
    12. A device according to any preceding claim, wherein the skin-contacting surface (14; 50; 64; 104) is provided with an aperture (29; 76) through which the delivery needle (21; 69; 102; 129; 131) extends in use.
    13. A device according to any preceding claim, when dependent on Claim 5, wherein an end of the cartridge (12; 48; 61; 91; 112) is provided with a stopper (9; 67; 99; 122) and the conduit (22; 101) and stopper (19; 67; 99; 122) are movable relative to one another to allow the conduit (22; 101) to penetrate through the stopper (19; 67; 99; 122) and thereby establish said communication.
    14. A device according to Claim 13, wherein the position of the needle assembly (20; 100) is fixed with respect to the cartridge (12; 112), and the stopper (19; 122) is movable relative to both the cartridge (12; 48; 112) and the needle assembly (20; 100).
    15. A device according to Claim 14, wherein the actuation of the expelling means (23, 24; 42, 43, 44; 113; 114) causes the stopper (19; 122) to be pressed onto and penetrated by the conduit (22; 122a).
    16. A device according to Claim 13, wherein the position of the stopper (67; 99) is fixed with respect to the cartridge (61; 91), and the needle assembly (68; 100) is movable relative to both the cartridge (61; 91) and the stopper (67; 99).
    17. A device according to any preceding claim, wherein the expelling means comprises a pre-compressed spring (23; 113).
    18. A device according to Claim 17, wherein the mechanism for actuating the expelling means (23, 24; 113; 114) comprises a catch (26; 116) which when released enables the pre-compressed spring (23; 113) to relax.
    19. A device according to Claim 18 wherein said relative movement causes the catch (26; 116) to be released.
    20. A device according to any one of Claims 1-16, wherein the expelling means comprises a gas generator (42, 43, 44; 97, 98) which generates a gas when two or more reactants are brought into contact.
    21. A device according to Claim 20, wherein the gas generator (42, 43, 44; 97, 98) comprises at least one liquid (42; 97).
    22. A device according to Claim 21, wherein the gas generator comprises the components of an effervescent couple (42, 43; 97, 98).
    23. A device according to any one of Claims 1-16, wherein the expelling means (72, 73; 80) comprises a material (85) which swells in the presence of a liquid, and also comprises a supply of said liquid.
    24. A device according to Claim 23, wherein said material is a swellable gel (85) and said liquid is water.
    25. A device according to any one of Claims 21-24, when dependent on Claim 8, wherein said liquid (42; 97) is contained within a rupturable compartment (44; 72) and the mechanism (45, 46; 71) for actuating the expelling means (42, 43, 44; 72, 73) comprises a penetrating member (45; 71), the penetrating member (45; 71) and the rupturable compartment (44; 72) being moved relative to one another upon the relative movement of the cartridge (48; 61) and the base member (49; 63), so as to cause the penetration of said rupturable compartment (44; 72) and the actuation of the expelling means (42, 43, 44; 72, 73).
    26. A device according to any preceding claim, when dependent on Claim 8, further comprising a snap mechanism (125, 126) which maintains a stable initial configuration and a stable working configuration and which when actuated causes the device (110) to snap from said initial configuration to said working configuration.
    27. A device according to Claim 26, further comprising resilient means (128) biasing the device (110) to said initial configuration and means (115, 116, 123, 124) for disengaging said snap mechanism (125, 126) when delivery has been completed.
    28. A device according to Claim 26 or 27, when dependent on Claim 2, wherein said disengaging means (115, 116, 123, 124) comprises a member (115, 123, 124) linked to said piston (111) such that when the piston (111) has completed the expulsion of drug from the drug compartment, said member (115, 123, 124) is caused to move and said movement causes the disengagement of said snap mechanism (125, 126), such that said resilient means (128) causes the device (110) to resume said initial configuration.
    29. A device according to any preceding claim, wherein said relative movement is a pivotal movement.
    30. A device according to Claim 29, wherein said delivery needle (21; 69; 102; 129) projects through the plane of the skin-contacting surface (14; 50; 64; 104) at or outside of the periphery of the skin-contacting surface (14; 50; 64; 104).
    31. A device according to Claim 30, wherein the delivery needle (131) is in the shape of a segment of arc of an imaginary circle, said circle having a radius equal to the distance between the delivery needle (131) and the hinge (140) and lying in a plane which is substantially normal to the plane of the skin-contacting surface.
    32. A device according to any one of Claims 1-31, wherein the delivery needle (21; 69; 102; 129) is straight.
    33. A liquid drug delivery device according to Claim 1, which comprises a drug cartridge assembly, to said assembly comprising:
      a columnar cartridge (12; 48; 61; 81; 91; 112) for containing drug, the cartridge (12; 48; 61; 81; 91; 112) having a first end and a second end;
      a piston (16; 41; 65; 83; 94; 111) slidably engaged at the first end of the cartridge (12; 48; 61; 81; 91; 112), the piston (16; 41; 65; 83; 94; 111) in communication with means (23, 24; 42, 43, 44; 72, 73; 85; 97, 98; 113, 114) for expelling the drug from the cartridge (12; 48; 61; 81; 91; 112); and
      a delivery needle assembly (20; 68; 100) fixed to the second end of the cartridge (12; 48; 61; 81; 91; 112), the delivery needle assembly (20; 68; 100) comprising a delivery needle (21; 69; 102; 129; 131) and a conduit (22; 101; 122a) enabling communication to be established during use between the drug compartment (17; 66; 84; 95) and the delivery needle (21; 69; 102; 129; 131).
    EP96945772A 1995-12-11 1996-12-11 Cartridge-based drug delivery device Expired - Lifetime EP0902696B1 (en)

    Applications Claiming Priority (3)

    Application Number Priority Date Filing Date Title
    US849995P 1995-12-11 1995-12-11
    US8499P 1995-12-11
    PCT/IE1996/000085 WO1997021457A1 (en) 1995-12-11 1996-12-11 Cartridge-based drug delivery device

    Publications (2)

    Publication Number Publication Date
    EP0902696A1 EP0902696A1 (en) 1999-03-24
    EP0902696B1 true EP0902696B1 (en) 2002-03-27

    Family

    ID=21731948

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP96945772A Expired - Lifetime EP0902696B1 (en) 1995-12-11 1996-12-11 Cartridge-based drug delivery device

    Country Status (11)

    Country Link
    US (1) US5858001A (en)
    EP (1) EP0902696B1 (en)
    JP (1) JP2000515394A (en)
    AT (1) ATE214954T1 (en)
    AU (1) AU1808797A (en)
    CA (1) CA2238614A1 (en)
    DE (1) DE69620257T2 (en)
    IL (1) IL124470A0 (en)
    TW (1) TW317503B (en)
    WO (1) WO1997021457A1 (en)
    ZA (1) ZA9610374B (en)

    Cited By (3)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US8070726B2 (en) 2003-04-23 2011-12-06 Valeritas, Inc. Hydraulically actuated pump for long duration medicament administration
    US8361053B2 (en) 2006-03-30 2013-01-29 Valeritas, Inc. Multi-cartridge fluid delivery device
    US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof

    Families Citing this family (528)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US6221056B1 (en) * 1996-12-20 2001-04-24 David G. Silverman Strong diaphragm/safe needle units and components for transfer of fluids
    US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
    JP2002505601A (en) 1997-06-16 2002-02-19 エラン コーポレーション ピーエルシー Pre-filled drug delivery device and method of making and assembling the same
    US6500150B1 (en) * 1997-06-16 2002-12-31 Elan Pharma International Limited Pre-filled drug-delivery device and method of manufacture and assembly of same
    IE970782A1 (en) 1997-10-22 1999-05-05 Elan Corp An improved automatic syringe
    CA2325004A1 (en) 1998-03-23 1999-09-30 Ehoud Carmel Drug delivery device
    US6126637A (en) * 1998-04-15 2000-10-03 Science Incorporated Fluid delivery device with collapsible needle cover
    US6355021B1 (en) * 1998-07-14 2002-03-12 Maersk Medical A/S Medical puncturing device
    US6428528B2 (en) 1998-08-11 2002-08-06 Antares Pharma, Inc. Needle assisted jet injector
    CA2350706A1 (en) 1998-11-13 2000-05-25 Elan Pharma International Limited Drug delivery systems and methods
    US6406455B1 (en) * 1998-12-18 2002-06-18 Biovalve Technologies, Inc. Injection devices
    US6461331B1 (en) 1999-05-21 2002-10-08 Minimed Inc. Device and method for infusion of small molecule insulin mimetic materials
    US6464628B1 (en) 1999-08-12 2002-10-15 Obtech Medical Ag Mechanical anal incontinence
    US6482145B1 (en) 2000-02-14 2002-11-19 Obtech Medical Ag Hydraulic anal incontinence treatment
    US6471635B1 (en) 2000-02-10 2002-10-29 Obtech Medical Ag Anal incontinence disease treatment with controlled wireless energy supply
    US6461292B1 (en) 1999-08-12 2002-10-08 Obtech Medical Ag Anal incontinence treatment with wireless energy supply
    EP1220697B1 (en) 1999-10-11 2004-12-29 Felton International, Inc. Universal anti-infectious protector for needleless injectors
    US7074210B2 (en) * 1999-10-11 2006-07-11 Felton International, Inc. Universal protector cap with auto-disable features for needle-free injectors
    US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
    US6391003B1 (en) 1999-10-25 2002-05-21 Antares Pharma, Inc. Locking mechanism for a jet injector
    US6770054B1 (en) 1999-11-23 2004-08-03 Felton International, Inc. Injector assembly with driving means and locking means
    US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
    WO2001051109A1 (en) * 2000-01-07 2001-07-19 Biovalve Technologies, Inc. Injection device
    DE60110747T2 (en) * 2000-02-10 2006-02-23 Potencia Medical Ag MECHANICAL DEVICE FOR IMPOTENCE TREATMENT
    DE60113377T2 (en) * 2000-02-10 2006-06-14 Potencia Medical Ag CONTROLLED HARNINE INCONTINENCE TREATMENT
    MXPA02007649A (en) 2000-02-10 2004-08-23 Potencia Medical Ag Urinary incontinence treatment with wireless energy supply.
    US20030125768A1 (en) * 2000-02-11 2003-07-03 Forsell Peter Impotence treatment apparatus with energy transforming means
    ATE380006T1 (en) * 2000-02-11 2007-12-15 Potencia Medical Ag CONTROLLED IMPOTENCY TREATMENT
    DE60111019T2 (en) 2000-02-14 2006-05-11 Potencia Medical Ag PROSTHESIS
    US20030100929A1 (en) 2000-02-14 2003-05-29 Peter Forsell Controlled penile prosthesis
    CA2397284C (en) * 2000-02-14 2010-05-18 Potencia Medical Ag Male impotence prosthesis apparatus with wireless energy supply
    IL137431A0 (en) 2000-07-20 2001-07-24 Slo Flo Ltd A new slow release device for controlled delivery of liquid material
    US6572586B1 (en) 2000-07-25 2003-06-03 Animas Corporation Low profile infusion set
    US6719721B1 (en) * 2000-10-23 2004-04-13 Elizabeth Okazaki Safety port needle assembly
    US7150409B2 (en) * 2000-11-30 2006-12-19 Biovalve Technologies, Inc. Injection systems
    US6579267B2 (en) * 2001-01-05 2003-06-17 Applied Diabetes Research, Inc. Pivoting joint infusion assembly
    US8343115B2 (en) * 2001-01-05 2013-01-01 Applied Diabetes Research, Inc. Low profile pivoting joint infusion assembly
    US7083597B2 (en) * 2001-01-05 2006-08-01 Applied Diabetes Research, Inc. Pivoting joint infusion system with seal
    US6982264B2 (en) * 2001-06-27 2006-01-03 Elan Pharmaceuticals, Inc. Substituted alcohols useful in treatment of Alzheimer's disease
    DE10142418A1 (en) 2001-08-31 2003-04-03 Molecular And Clinical Drug Re drug
    US20030088238A1 (en) * 2001-09-26 2003-05-08 Poulsen Jens Ulrik Modular drug delivery system
    US20060122577A1 (en) * 2001-09-26 2006-06-08 Poulsen Jens U Modular drug delivery system
    US6830562B2 (en) * 2001-09-27 2004-12-14 Unomedical A/S Injector device for placing a subcutaneous infusion set
    US6613015B2 (en) * 2001-10-04 2003-09-02 Deltec, Inc. Right angle safety needle
    US7429258B2 (en) * 2001-10-26 2008-09-30 Massachusetts Institute Of Technology Microneedle transport device
    US20040078028A1 (en) * 2001-11-09 2004-04-22 Flaherty J. Christopher Plunger assembly for patient infusion device
    US7407490B2 (en) 2001-11-29 2008-08-05 Novo Nordisk A/S Delivery device and cartridge therefore
    US20030109827A1 (en) * 2001-12-07 2003-06-12 Elan Pharma International Limited Drug delivery system and method
    ITTO20011228A1 (en) * 2001-12-28 2003-06-28 Cane Srl DISPOSABLE NEEDLE CONTAINER.
    ATE409057T1 (en) 2002-02-11 2008-10-15 Antares Pharma Inc INTRADERMAL INJECTION DEVICE
    AU2003208296A1 (en) * 2002-02-12 2003-09-04 Unomedial A/S Infusion device with needle shield
    DE10206910A1 (en) * 2002-02-19 2003-09-04 Disetronic Licensing Ag Device for administering an injectable product
    MXPA04008660A (en) 2002-03-08 2005-06-08 Applied Diabetes Res Inc Low profile, pivotal connection infusion assembly.
    ES2673480T3 (en) 2002-03-26 2018-06-22 Becton, Dickinson And Company Multi-stage fluid supply device and method
    US20030195609A1 (en) * 2002-04-10 2003-10-16 Scimed Life Systems, Inc. Hybrid stent
    JP4764626B2 (en) 2002-05-06 2011-09-07 ベクトン・ディキンソン・アンド・カンパニー Method and device for controlling the pharmacokinetics of a drug
    US6723072B2 (en) * 2002-06-06 2004-04-20 Insulet Corporation Plunger assembly for patient infusion device
    CA2493728C (en) * 2002-07-22 2013-10-29 Becton, Dickinson And Company Patch-like infusion device
    JP2005533545A (en) 2002-07-24 2005-11-10 エム2・メディカル・アクティーゼルスカブ Infusion pump system, infusion pump unit, infusion pump
    US20040059316A1 (en) * 2002-07-31 2004-03-25 Smedegaard Jorgen K. Medical delivery device
    EP1386626A1 (en) 2002-07-31 2004-02-04 Novo Nordisk A/S Delivery device for treatment of diabetes mellitus
    US20040051019A1 (en) 2002-09-02 2004-03-18 Mogensen Lasse Wesseltoft Apparatus for and a method of adjusting the length of an infusion tube
    DK1556124T3 (en) * 2002-09-02 2008-02-18 Unomedical As Apparatus and method for adjusting the length of an infusion tube
    US7637891B2 (en) * 2002-09-12 2009-12-29 Children's Hospital Medical Center Method and device for painless injection of medication
    WO2004030726A1 (en) * 2002-10-07 2004-04-15 Novo Nordisk A/S Needle device comprising a plurality of needles
    US20050075670A1 (en) * 2002-10-07 2005-04-07 Henrik Bengtsson Signal device with electro-muscle stimulation feature
    US7014625B2 (en) * 2002-10-07 2006-03-21 Novo Nordick A/S Needle insertion device
    US7727181B2 (en) 2002-10-09 2010-06-01 Abbott Diabetes Care Inc. Fluid delivery device with autocalibration
    WO2004041330A2 (en) * 2002-11-05 2004-05-21 M 2 Medical A/S A disposable wearable insulin dispensing device, a combination of such a device and a programming controller and a method of controlling the operation of such a device
    US7381184B2 (en) * 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
    US6896666B2 (en) * 2002-11-08 2005-05-24 Kochamba Family Trust Cutaneous injection delivery under suction
    US20060264926A1 (en) * 2002-11-08 2006-11-23 Kochamba Gary S Cutaneous stabilization by vacuum for delivery of micro-needle array
    DK200201823A (en) * 2002-11-26 2004-05-27 Maersk Medical As Connection piece for a hose connection
    CN1738656A (en) 2002-12-23 2006-02-22 M2医药有限公司 Disposable, wearable insulin dispensing device, a combination of such a device and a programming controller and a method of controlling the operation of such a device
    US7252651B2 (en) * 2003-01-07 2007-08-07 Becton, Dickinson And Company Disposable injection device
    DE10300896A1 (en) 2003-01-13 2004-07-22 Disetronic Licensing Ag Automatic delivery device driven by hydrogels with adjustable delivery characteristics to deliver a medium, especially insulin
    IL154243A0 (en) * 2003-02-02 2003-09-17 Silex Projectors Ltd Stable infusion device
    US20040158202A1 (en) * 2003-02-12 2004-08-12 Soren Jensen Cover
    US20060069382A1 (en) * 2003-04-11 2006-03-30 Novo Nordisk A/S Delivery device
    EP1624915A1 (en) 2003-04-11 2006-02-15 Novo Nordisk A/S Delivery device
    US7679407B2 (en) * 2003-04-28 2010-03-16 Abbott Diabetes Care Inc. Method and apparatus for providing peak detection circuitry for data communication systems
    TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
    EP1475113A1 (en) * 2003-05-08 2004-11-10 Novo Nordisk A/S External needle inserter
    ATE392223T1 (en) * 2003-05-08 2008-05-15 Novo Nordisk As INTERNAL NEEDLE INTRODUCER
    CN100574819C (en) * 2003-05-08 2009-12-30 诺沃挪第克公司 Pivotable needle unit
    ATE474611T1 (en) * 2003-05-08 2010-08-15 Novo Nordisk As AN INJECTION DEVICE THAT CAN BE APPLIED TO THE SKIN WITH A SEPARABLE ACTUATING PART FOR INSERTING THE NEEDLE
    EP1495775A1 (en) * 2003-07-08 2005-01-12 Novo Nordisk A/S Portable drug delivery device having an encapsulated needle
    ATE357939T1 (en) * 2003-07-08 2007-04-15 Novo Nordisk As PORTABLE MEDICINE DELIVERY DEVICE HAVING AN ENCAPSULATED NEEDLE
    EP1502613A1 (en) * 2003-08-01 2005-02-02 Novo Nordisk A/S Needle device with retraction means
    US8444604B2 (en) 2003-08-12 2013-05-21 Becton, Dickinson And Company Patch-like infusion device
    US7766902B2 (en) * 2003-08-13 2010-08-03 Wisconsin Alumni Research Foundation Microfluidic device for drug delivery
    CA2536681C (en) 2003-08-28 2011-07-05 Becton, Dickinson And Company Intradermal injection device
    KR20060099520A (en) * 2003-10-21 2006-09-19 노보 노르디스크 에이/에스 Medical skin mountable device
    CA2543545A1 (en) 2003-10-21 2005-05-06 Ole Christian Nielsen Medical injection device mountable to the skin
    EP1527792A1 (en) 2003-10-27 2005-05-04 Novo Nordisk A/S Medical injection device mountable to the skin
    PL1682203T3 (en) 2003-10-23 2010-06-30 Novo Nordisk As Medical injection device mountable to the skin
    US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
    US7299082B2 (en) * 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
    USD914881S1 (en) 2003-11-05 2021-03-30 Abbott Diabetes Care Inc. Analyte sensor electronic mount
    ES2374530T3 (en) * 2003-12-11 2012-02-17 Ares Trading S.A. STABILIZED INTERFER LIQUID FORMULATIONS.
    US7896841B2 (en) * 2004-02-17 2011-03-01 Children's Hospital Medical Center Injection device for administering a vaccine
    DK1727576T3 (en) * 2004-03-26 2009-07-06 Unomedical As Infusion
    CN100586495C (en) * 2004-03-30 2010-02-03 诺和诺德公司 Actuator system comprising lever mechanism
    CN1938061B (en) * 2004-03-30 2010-10-06 诺和诺德公司 Actuator system comprising detector means
    DK1732627T3 (en) 2004-03-31 2010-08-16 Lilly Co Eli Injection apparatus having a needle cartridge for dispensing a pharmaceutical liquid
    US20070135697A1 (en) * 2004-04-19 2007-06-14 Therasense, Inc. Method and apparatus for providing sensor guard for data monitoring and detection systems
    US20050240154A1 (en) * 2004-04-21 2005-10-27 Unomedical A/S: Infusion set with patch
    EA012205B1 (en) * 2004-05-17 2009-08-28 Арес Трейдинг С.А. Hydrogel interferon formulations
    ES2418833T3 (en) 2004-06-01 2013-08-16 Ares Trading S.A. Stabilized interferon liquid formulations
    US8247946B2 (en) 2004-06-14 2012-08-21 Massachusetts Institute Of Technology Electrochemical actuator
    US7872396B2 (en) 2004-06-14 2011-01-18 Massachusetts Institute Of Technology Electrochemical actuator
    US7999435B2 (en) * 2004-06-14 2011-08-16 Massachusetts Institute Of Technology Electrochemical actuator
    WO2005124918A2 (en) 2004-06-14 2005-12-29 Massachusetts Institute Of Technology Electrochemical actuating methods, devices and structures
    US7994686B2 (en) * 2004-06-14 2011-08-09 Massachusetts Institute Of Technology Electrochemical methods, devices, and structures
    US8062250B2 (en) * 2004-08-10 2011-11-22 Unomedical A/S Cannula device
    DE102004039408A1 (en) * 2004-08-13 2006-03-02 Disetronic Licensing Ag Insertion head for medical or pharmaceutical applications
    CN101010112B (en) * 2004-09-02 2010-04-21 诺和诺德公司 Medical device adapted for detection of drug condition
    WO2006032692A1 (en) 2004-09-22 2006-03-30 Novo Nordisk A/S Medical device with cannula inserter
    US20080215006A1 (en) * 2004-09-22 2008-09-04 Novo Nordisk A/S Medical Device with Transcutaneous Cannula Device
    CN101087625B (en) * 2004-11-22 2012-02-22 因特利杰克特有限公司 Devices and systems for medicament delivery
    US10737028B2 (en) 2004-11-22 2020-08-11 Kaleo, Inc. Devices, systems and methods for medicament delivery
    US11590286B2 (en) 2004-11-22 2023-02-28 Kaleo, Inc. Devices, systems and methods for medicament delivery
    US7648483B2 (en) * 2004-11-22 2010-01-19 Intelliject, Inc. Devices, systems and methods for medicament delivery
    JP4874989B2 (en) 2004-11-22 2012-02-15 ノヴォ ノルディスク アー/エス Soluble and stable insulin-containing formulation
    US7947017B2 (en) 2004-11-22 2011-05-24 Intelliject, Inc. Devices, systems and methods for medicament delivery
    CN100579598C (en) 2004-12-06 2010-01-13 诺和诺德公司 Ventilated skin mountable device
    JP4964141B2 (en) * 2004-12-10 2012-06-27 ウノメディカル アクティーゼルスカブ Insertion tool
    US20070027381A1 (en) * 2005-07-29 2007-02-01 Therasense, Inc. Inserter and methods of use
    US10226207B2 (en) 2004-12-29 2019-03-12 Abbott Diabetes Care Inc. Sensor inserter having introducer
    US20100331646A1 (en) * 2009-06-30 2010-12-30 Abbott Diabetes Care Inc. Health Management Devices and Methods
    US7697967B2 (en) 2005-12-28 2010-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
    US7731657B2 (en) * 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
    US8571624B2 (en) * 2004-12-29 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for mounting a data transmission device in a communication system
    US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
    US8029441B2 (en) 2006-02-28 2011-10-04 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
    US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
    US20090105569A1 (en) 2006-04-28 2009-04-23 Abbott Diabetes Care, Inc. Introducer Assembly and Methods of Use
    US20110190603A1 (en) * 2009-09-29 2011-08-04 Stafford Gary A Sensor Inserter Having Introducer
    US9259175B2 (en) 2006-10-23 2016-02-16 Abbott Diabetes Care, Inc. Flexible patch for fluid delivery and monitoring body analytes
    US9572534B2 (en) 2010-06-29 2017-02-21 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
    US9788771B2 (en) 2006-10-23 2017-10-17 Abbott Diabetes Care Inc. Variable speed sensor insertion devices and methods of use
    US8333714B2 (en) 2006-09-10 2012-12-18 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
    US9636450B2 (en) * 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
    US9743862B2 (en) 2011-03-31 2017-08-29 Abbott Diabetes Care Inc. Systems and methods for transcutaneously implanting medical devices
    US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
    EP1841476B1 (en) * 2005-01-17 2011-06-29 Novo Nordisk A/S Fluid delivery device with integrated monitoring of physiological characteristics
    ES2908027T3 (en) 2005-01-24 2022-04-27 Antares Pharma Inc An injector with a pre-filled syringe
    EP1848476A1 (en) 2005-01-24 2007-10-31 Novo Nordisk A/S Transcutaneous device assembly
    PL2058020T3 (en) 2005-02-01 2013-03-29 Kaleo Inc Devices for medicament delivery
    EP1866009A1 (en) 2005-02-25 2007-12-19 Novo Nordisk A/S Pump assembly with safety valve
    US7985199B2 (en) 2005-03-17 2011-07-26 Unomedical A/S Gateway system
    EP1863559A4 (en) * 2005-03-21 2008-07-30 Abbott Diabetes Care Inc Method and system for providing integrated medication infusion and analyte monitoring system
    KR20070121731A (en) * 2005-03-21 2007-12-27 우노메디컬 에이/에스 A mounting pad, an adhesive device comprising such mounting pad, and methods of applying such devices to a patient
    WO2006105794A1 (en) 2005-04-06 2006-10-12 M 2 Medical A/S An actuator
    EP1877116A1 (en) 2005-04-13 2008-01-16 Novo Nordisk A/S Medical skin mountable device and system
    US20080097291A1 (en) * 2006-08-23 2008-04-24 Hanson Ian B Infusion pumps and methods and delivery devices and methods with same
    US8277415B2 (en) * 2006-08-23 2012-10-02 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
    US8137314B2 (en) * 2006-08-23 2012-03-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with compressible or curved reservoir or conduit
    US7955305B2 (en) 2005-05-06 2011-06-07 Medtronic Minimed, Inc. Needle inserter and method for infusion device
    US8512288B2 (en) * 2006-08-23 2013-08-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
    US7905868B2 (en) * 2006-08-23 2011-03-15 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
    US8840586B2 (en) * 2006-08-23 2014-09-23 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
    EP1898975A2 (en) * 2005-05-13 2008-03-19 Novo Nordisk A/S Medical device adapted to detect disengagement of a transcutaneous device
    US7768408B2 (en) 2005-05-17 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
    DK1896097T3 (en) * 2005-06-28 2010-11-22 Unomedical As Packaging for infusion sets and method of using an infusion set
    US8603034B2 (en) * 2005-07-12 2013-12-10 Applied Diabetes Research, Inc. One piece sealing reservoir for an insulin infusion pump
    PL1762259T3 (en) 2005-09-12 2011-03-31 Unomedical As Inserter for an infusion set with a first and second spring units
    DE502005009907D1 (en) * 2005-09-15 2010-08-26 Roche Diagnostics Gmbh Insertion head with handle
    US9144645B2 (en) * 2005-09-21 2015-09-29 Applied Diabetes Research, Inc. One piece sealing reservoir for an insulin infusion pump
    US8105279B2 (en) 2005-09-26 2012-01-31 M2 Group Holdings, Inc. Dispensing fluid from an infusion pump system
    US7534226B2 (en) 2005-09-26 2009-05-19 M2 Group Holdings, Inc. Dispensing fluid from an infusion pump system
    US8409142B2 (en) 2005-09-26 2013-04-02 Asante Solutions, Inc. Operating an infusion pump system
    EP1933901B1 (en) 2005-09-26 2014-12-31 Asante Solutions, Inc. Portable infusion pump having a flexible pushrod with hinged portions
    US8545445B2 (en) * 2006-02-09 2013-10-01 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
    US9521968B2 (en) * 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
    US7756561B2 (en) * 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
    US8880138B2 (en) * 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
    JP2009511223A (en) * 2005-10-17 2009-03-19 ノボ・ノルデイスク・エー/エス Vented drug reservoir unit
    US7583190B2 (en) * 2005-10-31 2009-09-01 Abbott Diabetes Care Inc. Method and apparatus for providing data communication in data monitoring and management systems
    SI2926847T1 (en) * 2005-11-02 2022-10-28 Medicaltree Patents Ltd. Implantable infusion device with advanceable and retractable needle
    WO2007056592A2 (en) 2005-11-08 2007-05-18 M2 Medical A/S Method and system for manual and autonomous control of an infusion pump
    JP4768415B2 (en) * 2005-11-24 2011-09-07 テルモ株式会社 Puncture device
    US20090118592A1 (en) * 2005-12-08 2009-05-07 Novo Nordisk A/S Medical System Comprising a Sensor Device
    USD655807S1 (en) 2005-12-09 2012-03-13 Unomedical A/S Medical device
    ATE429260T1 (en) * 2005-12-23 2009-05-15 Unomedical As ADMINISTRATION DEVICE
    US11298058B2 (en) 2005-12-28 2022-04-12 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
    US7549976B2 (en) * 2005-12-28 2009-06-23 Smiths Medical Md, Inc. Portal access device with removable sharps protection
    EP1968432A4 (en) * 2005-12-28 2009-10-21 Abbott Diabetes Care Inc Medical device insertion
    US20070264130A1 (en) * 2006-01-27 2007-11-15 Phluid, Inc. Infusion Pumps and Methods for Use
    US20090218243A1 (en) * 2006-02-13 2009-09-03 Unomedical A/S Packing for Injection Device
    NZ570115A (en) * 2006-02-28 2010-07-30 Unomedical As Inserter for infusion part and infusion part provided with needle protector
    US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
    US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
    WO2007104755A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Secure pairing of electronic devices using dual means of communication
    WO2007122207A1 (en) 2006-04-26 2007-11-01 Novo Nordisk A/S Skin-mountable device in packaging comprising coated seal member
    WO2007131013A1 (en) 2006-05-03 2007-11-15 Antares Pharma, Inc. Two-stage reconstituting injector
    EP1857129B8 (en) * 2006-05-19 2009-09-02 Roche Diagnostics GmbH Adapter device for sticking a medical instrument to the skin surface
    US20070282269A1 (en) * 2006-05-31 2007-12-06 Seattle Medical Technologies Cannula delivery apparatus and method for a disposable infusion device
    US20070287960A1 (en) * 2006-05-31 2007-12-13 Seattle Medical Technologies Disposable infusion device with medicament level indicator
    US7713262B2 (en) * 2006-05-31 2010-05-11 Calibra Medical, Inc. Disposable infusion device with linear peristaltic pump
    US9399094B2 (en) * 2006-06-06 2016-07-26 Novo Nordisk A/S Assembly comprising skin-mountable device and packaging therefore
    EP2023818A2 (en) * 2006-06-07 2009-02-18 Unomedical A/S Inserter for transcutaneous sensor
    CN101489604B (en) * 2006-06-09 2012-05-23 优诺医疗有限公司 Mounting pad
    CN101500627B (en) 2006-08-02 2012-03-14 优诺医疗有限公司 Cannula and delivery device
    US20080051765A1 (en) * 2006-08-23 2008-02-28 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
    US7828764B2 (en) * 2006-08-23 2010-11-09 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
    US7789857B2 (en) * 2006-08-23 2010-09-07 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
    US7794434B2 (en) * 2006-08-23 2010-09-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
    US7811262B2 (en) * 2006-08-23 2010-10-12 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
    US8870821B2 (en) * 2006-10-13 2014-10-28 Michael D. Laufer Device for tissue injection
    EP1917990A1 (en) 2006-10-31 2008-05-07 Unomedical A/S Infusion set
    US8579853B2 (en) * 2006-10-31 2013-11-12 Abbott Diabetes Care Inc. Infusion devices and methods
    CN101541359B (en) * 2006-11-21 2012-11-28 皇家飞利浦电子股份有限公司 Medicament delivery device, capsule and in vivo medicine delivery or diagnostic system
    US20080161666A1 (en) * 2006-12-29 2008-07-03 Abbott Diabetes Care, Inc. Analyte devices and methods
    AU2008209700A1 (en) * 2007-02-02 2008-08-07 Unomedical A/S A gateway device
    EP2114492A1 (en) * 2007-03-06 2009-11-11 Novo Nordisk A/S Pump assembly comprising actuator system
    DE502007005457D1 (en) * 2007-03-14 2010-12-09 Roche Diagnostics Gmbh Insertion head for medical or pharmaceutical applications
    ATE477011T1 (en) * 2007-03-14 2010-08-15 Hoffmann La Roche INSERTION DEVICE FOR AN INSERTION HEAD, IN PARTICULAR FOR AN INFUSION SET
    JP5102350B2 (en) * 2007-04-30 2012-12-19 メドトロニック ミニメド インコーポレイテッド Reservoir filling / bubble management / infusion medium delivery system and method using the system
    US7959715B2 (en) * 2007-04-30 2011-06-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
    US7963954B2 (en) 2007-04-30 2011-06-21 Medtronic Minimed, Inc. Automated filling systems and methods
    US8323250B2 (en) * 2007-04-30 2012-12-04 Medtronic Minimed, Inc. Adhesive patch systems and methods
    US8434528B2 (en) * 2007-04-30 2013-05-07 Medtronic Minimed, Inc. Systems and methods for reservoir filling
    US8613725B2 (en) 2007-04-30 2013-12-24 Medtronic Minimed, Inc. Reservoir systems and methods
    US8597243B2 (en) 2007-04-30 2013-12-03 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
    ES2911529T3 (en) * 2007-05-07 2022-05-19 Unomedical As supply device
    US7892199B2 (en) 2007-05-21 2011-02-22 Asante Solutions, Inc. Occlusion sensing for an infusion pump
    US7833196B2 (en) * 2007-05-21 2010-11-16 Asante Solutions, Inc. Illumination instrument for an infusion pump
    US7794426B2 (en) 2007-05-21 2010-09-14 Asante Solutions, Inc. Infusion pump system with contamination-resistant features
    US7981102B2 (en) * 2007-05-21 2011-07-19 Asante Solutions, Inc. Removable controller for an infusion pump
    WO2008150917A1 (en) * 2007-05-31 2008-12-11 Abbott Diabetes Care, Inc. Insertion devices and methods
    US20100190706A1 (en) 2007-06-01 2010-07-29 Novo Nordisk A/S Stable Non-Aqueous Pharmaceutical Compositions
    ES2351273T3 (en) * 2007-06-06 2011-02-02 Unomedical A/S PACKING THAT ALLOWS GAS STERILIZATION.
    US20080312600A1 (en) * 2007-06-15 2008-12-18 Peter Krulevitch Flexible medical device conduit
    EP2155296B1 (en) * 2007-06-20 2019-08-28 Unomedical A/S Cannula insertion device with automatic needle retraction comprising only one spring
    DE202008017390U1 (en) 2007-06-20 2009-08-13 Unomedical A/S Catheter and device for making such a catheter
    WO2009004026A1 (en) 2007-07-03 2009-01-08 Unomedical A/S Inserter having bistable equilibrium states
    RU2010104457A (en) 2007-07-10 2011-08-20 Уномедикал А/С (Dk) TWO SPRING INPUT DEVICE
    RU2010105684A (en) * 2007-07-18 2011-08-27 Уномедикал А/С (Dk) TURNING INTRODUCTION DEVICE
    US7828771B2 (en) * 2007-07-26 2010-11-09 Entra Pharmaceuticals, Inc. Systems and methods for delivering drugs
    US7717903B2 (en) 2007-09-06 2010-05-18 M2 Group Holdings, Inc. Operating an infusion pump system
    US8032226B2 (en) 2007-09-07 2011-10-04 Asante Solutions, Inc. User profile backup system for an infusion pump device
    US8287514B2 (en) 2007-09-07 2012-10-16 Asante Solutions, Inc. Power management techniques for an infusion pump system
    US7935076B2 (en) 2007-09-07 2011-05-03 Asante Solutions, Inc. Activity sensing techniques for an infusion pump system
    US8062256B2 (en) * 2007-09-28 2011-11-22 Calibra Medical, Inc. Disposable infusion device with medicament level indicator
    US10420880B2 (en) 2007-10-02 2019-09-24 West Pharma. Services IL, Ltd. Key for securing components of a drug delivery system during assembly and/or transport and methods of using same
    US9345836B2 (en) 2007-10-02 2016-05-24 Medimop Medical Projects Ltd. Disengagement resistant telescoping assembly and unidirectional method of assembly for such
    US7967795B1 (en) 2010-01-19 2011-06-28 Lamodel Ltd. Cartridge interface assembly with driving plunger
    WO2009044401A2 (en) 2007-10-02 2009-04-09 Yossi Gross External drug pump
    US9656019B2 (en) * 2007-10-02 2017-05-23 Medimop Medical Projects Ltd. Apparatuses for securing components of a drug delivery system during transport and methods of using same
    EP2209500B1 (en) * 2007-10-31 2015-07-22 Novo Nordisk A/S Non-porous material as sterilization barrier
    ES2387236T3 (en) * 2007-12-20 2012-09-18 Merck Serono S.A. Pegylated interferon beta formulations
    US8986253B2 (en) * 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
    WO2009096855A1 (en) * 2008-01-28 2009-08-06 Milux Holding Sa Blood clot removal device, system, and method
    EP2240140B8 (en) * 2008-01-29 2022-05-18 Implantica Patent Ltd. An apparatus for treating gerd
    EP2452709B1 (en) * 2008-02-08 2022-01-19 Unomedical A/S Cannula part
    US20110046456A1 (en) * 2008-02-08 2011-02-24 Hoerdum Elo Lau Assembly Comprising Inserter, Cannula Part and Base Part
    US20090204077A1 (en) * 2008-02-13 2009-08-13 Hasted Soren B Moulded Connection Between Cannula and Delivery Part
    NZ587111A (en) * 2008-02-13 2012-03-30 Unomedical As Infusion part including seal between cannula and fluid inlet or outlet
    AU2009216703A1 (en) 2008-02-20 2009-08-27 Unomedical A/S Insertion device with horizontally moving part
    BRPI0908258A2 (en) * 2008-02-25 2017-10-17 Unomedical As membrane completely covering an opening of a needle giving access to a space in a device, device and assembly comprising a device
    US20090247982A1 (en) * 2008-03-27 2009-10-01 Lifescan Inc. Medical Device Mechanical Pump
    WO2009143188A2 (en) * 2008-05-19 2009-11-26 Diperna Paul M Disposable pump reservoir and related methods
    US20110005958A1 (en) * 2009-07-09 2011-01-13 Onpharma, Inc. METHODS AND SYSTEMS FOR ADJUSTING THE pH OF MEDICAL BUFFERING SOLUTIONS
    WO2010003886A1 (en) * 2008-07-07 2010-01-14 Unomedical A/S Inserter for transcutaneous device
    US8876755B2 (en) 2008-07-14 2014-11-04 Abbott Diabetes Care Inc. Closed loop control system interface and methods
    ES2738539T3 (en) 2008-08-05 2020-01-23 Antares Pharma Inc Multi dose injector
    CN102186515B (en) * 2008-08-18 2014-07-23 凯利宝医疗公司 Drug infusion system with reusable and disposable components
    US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
    US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
    US8408421B2 (en) * 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
    AU2009293019A1 (en) * 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
    US20110226652A1 (en) * 2008-09-29 2011-09-22 Richard Morgan Hickmott Packing for Inserter
    US8509894B2 (en) 2008-10-10 2013-08-13 Milux Holding Sa Heart help device, system, and method
    EP2346548B1 (en) * 2008-10-10 2021-06-16 MedicalTree Patent Ltd. Heart help device, and system
    EP2349096B1 (en) 2008-10-10 2021-01-27 MedicalTree Patent Ltd. An improved artificial valve
    WO2010042046A1 (en) 2008-10-10 2010-04-15 Milux Holding S.A. Apparatus, system and operation method for the treatment of female sexual dysfunction
    US8874215B2 (en) 2008-10-10 2014-10-28 Peter Forsell System, an apparatus, and a method for treating a sexual dysfunctional female patient
    US11123171B2 (en) * 2008-10-10 2021-09-21 Peter Forsell Fastening means for implantable medical control assembly
    US20100145305A1 (en) * 2008-11-10 2010-06-10 Ruth Alon Low volume accurate injector
    US20100130958A1 (en) * 2008-11-26 2010-05-27 David Kang Device and Methods for Subcutaneous Delivery of High Viscosity Fluids
    KR20110127642A (en) 2008-12-22 2011-11-25 우노메디컬 에이/에스 Medical device comprising adhesive pad
    US8152779B2 (en) * 2008-12-30 2012-04-10 Medimop Medical Projects Ltd. Needle assembly for drug pump
    ES2688062T3 (en) 2009-01-12 2018-10-30 Becton, Dickinson And Company Infusion set and / or patch pump having at least one of a rigid internal permanence catheter with flexible features and / or a flexible catheter connection
    US9375529B2 (en) * 2009-09-02 2016-06-28 Becton, Dickinson And Company Extended use medical device
    US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
    US8807169B2 (en) 2009-02-12 2014-08-19 Picolife Technologies, Llc Flow control system for a micropump
    US20100217233A1 (en) * 2009-02-20 2010-08-26 Ranft Elizabeth A Method and device to anesthetize an area
    DK3714788T3 (en) * 2009-02-26 2023-04-17 Abbott Diabetes Care Inc Method for manufacturing improved analyte sensors
    US8579865B2 (en) 2009-03-20 2013-11-12 Antares Pharma, Inc. Hazardous agent injection system
    US8467972B2 (en) * 2009-04-28 2013-06-18 Abbott Diabetes Care Inc. Closed loop blood glucose control algorithm analysis
    WO2010127052A1 (en) * 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Dynamic analyte sensor calibration based on sensor stability profile
    US9949812B2 (en) 2009-07-17 2018-04-24 Peter Forsell Vaginal operation method for the treatment of anal incontinence in women
    US10952836B2 (en) * 2009-07-17 2021-03-23 Peter Forsell Vaginal operation method for the treatment of urinary incontinence in women
    US8939928B2 (en) 2009-07-23 2015-01-27 Becton, Dickinson And Company Medical device having capacitive coupling communication and energy harvesting
    EP3689237B1 (en) * 2009-07-23 2021-05-19 Abbott Diabetes Care, Inc. Method of manufacturing and system for continuous analyte measurement
    EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
    KR20120054598A (en) 2009-07-30 2012-05-30 우노메디컬 에이/에스 Inserter device with horizontal moving part
    CA2766961A1 (en) 2009-08-07 2011-02-10 Unomedical A/S Delivery device with sensor and one or more cannulas
    WO2011025999A1 (en) * 2009-08-29 2011-03-03 Abbott Diabetes Care Inc. Analyte sensor
    WO2011026149A1 (en) * 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Mounting unit having a sensor and associated circuitry
    CN102473276B (en) 2009-08-31 2016-04-13 雅培糖尿病护理公司 Medical treatment device and method
    WO2011026130A1 (en) * 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Inserter device including rotor subassembly
    US10092691B2 (en) 2009-09-02 2018-10-09 Becton, Dickinson And Company Flexible and conformal patch pump
    USD811584S1 (en) 2009-09-15 2018-02-27 Medimop Medical Projects Ltd. Injector device
    US10071196B2 (en) 2012-05-15 2018-09-11 West Pharma. Services IL, Ltd. Method for selectively powering a battery-operated drug-delivery device and device therefor
    US10071198B2 (en) 2012-11-02 2018-09-11 West Pharma. Servicees IL, Ltd. Adhesive structure for medical device
    US8157769B2 (en) * 2009-09-15 2012-04-17 Medimop Medical Projects Ltd. Cartridge insertion assembly for drug delivery system
    WO2011041531A1 (en) 2009-09-30 2011-04-07 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
    CN104474605B (en) * 2009-10-13 2017-12-19 瓦莱里塔斯公司 Fluid delivery system
    ES2929490T3 (en) 2009-12-16 2022-11-29 Becton Dickinson Co self injection device
    ES2537654T3 (en) 2009-12-16 2015-06-10 Becton Dickinson And Company Auto injection device
    ES2714698T3 (en) 2009-12-16 2019-05-29 Becton Dickinson Co Auto injection device
    CN102753213B (en) 2009-12-16 2015-04-29 贝克顿·迪金森公司 Self-injection device
    IN2012DN05226A (en) 2009-12-16 2015-10-23 Becton Dickinson Co
    US9717850B2 (en) 2009-12-16 2017-08-01 Becton, Dickinson And Company Self-injection device
    US8348898B2 (en) 2010-01-19 2013-01-08 Medimop Medical Projects Ltd. Automatic needle for drug pump
    USD924406S1 (en) 2010-02-01 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor inserter
    KR20130038841A (en) 2010-03-19 2013-04-18 할로자임, 아이엔씨 Gas-pressured medication delivery device
    WO2011162843A1 (en) 2010-03-24 2011-12-29 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
    BR112012024635A2 (en) 2010-03-30 2017-08-08 Unomedical As medical device
    US8337457B2 (en) 2010-05-05 2012-12-25 Springleaf Therapeutics, Inc. Systems and methods for delivering a therapeutic agent
    US9452261B2 (en) 2010-05-10 2016-09-27 Medimop Medical Projects Ltd. Low volume accurate injector
    AU2015203703B2 (en) * 2010-05-20 2018-01-18 Becton, Dickinson And Company Drug delivery device
    AU2011256804B2 (en) * 2010-05-20 2013-10-17 Becton, Dickinson And Company Drug delivery device
    AU2014200306B2 (en) * 2010-05-20 2015-04-02 Becton, Dickinson And Company Drug delivery device
    USD669165S1 (en) 2010-05-27 2012-10-16 Asante Solutions, Inc. Infusion pump
    HUE026173T2 (en) 2010-06-07 2016-05-30 Amgen Inc Drug delivery device
    US11064921B2 (en) 2010-06-29 2021-07-20 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
    US20110319861A1 (en) * 2010-06-29 2011-12-29 Robert Wilk Medical device mechanical pump
    US8260427B2 (en) 2010-07-07 2012-09-04 ProNerve, LLC Garment to facilitate needle electrode placement for intraoperative monitoring
    EP2611478B1 (en) 2010-09-02 2022-08-17 Becton, Dickinson and Company Self-injection device having needle cover with activation preventer
    US20120071837A1 (en) * 2010-09-21 2012-03-22 O'connor Sean Auto injector for medication
    US8585677B2 (en) 2010-09-21 2013-11-19 Brigham Young University Laminar injection apparatus and method
    US8915879B2 (en) 2010-09-24 2014-12-23 Perqflo, Llc Infusion pumps
    US9216249B2 (en) 2010-09-24 2015-12-22 Perqflo, Llc Infusion pumps
    US9498573B2 (en) 2010-09-24 2016-11-22 Perqflo, Llc Infusion pumps
    US8777901B2 (en) 2010-09-24 2014-07-15 Perqflo, Llc Infusion pumps
    EP2433663A1 (en) 2010-09-27 2012-03-28 Unomedical A/S Insertion system
    EP2436412A1 (en) 2010-10-04 2012-04-04 Unomedical A/S A sprinkler cannula
    WO2012059457A1 (en) * 2010-11-03 2012-05-10 Sanofi-Aventis Deutschland Gmbh Medicated module for administering fixed dose
    US8905972B2 (en) 2010-11-20 2014-12-09 Perqflo, Llc Infusion pumps
    US9950109B2 (en) 2010-11-30 2018-04-24 Becton, Dickinson And Company Slide-activated angled inserter and cantilevered ballistic insertion for intradermal drug infusion
    US8814831B2 (en) 2010-11-30 2014-08-26 Becton, Dickinson And Company Ballistic microneedle infusion device
    US8795230B2 (en) 2010-11-30 2014-08-05 Becton, Dickinson And Company Adjustable height needle infusion device
    CA2821979A1 (en) 2010-12-17 2012-06-21 Yet-Ming Chiang Electrochemical actuators
    US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
    US9084849B2 (en) 2011-01-26 2015-07-21 Kaleo, Inc. Medicament delivery devices for administration of a medicament within a prefilled syringe
    US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
    US8852152B2 (en) 2011-02-09 2014-10-07 Asante Solutions, Inc. Infusion pump systems and methods
    US8454581B2 (en) 2011-03-16 2013-06-04 Asante Solutions, Inc. Infusion pump systems and methods
    USD702834S1 (en) 2011-03-22 2014-04-15 Medimop Medical Projects Ltd. Cartridge for use in injection device
    CN103619378B (en) * 2011-04-21 2017-03-01 艾伯维公司 wearable automatic injection device
    US20120283668A1 (en) * 2011-05-04 2012-11-08 Pinchas Shalev Apparatus and method for using effervescent tablets for cosmetic care
    EP2535073A1 (en) * 2011-06-16 2012-12-19 F. Hoffmann-La Roche AG Transport and transfer container for a fluid medium
    US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
    US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
    US9814832B2 (en) 2011-09-02 2017-11-14 Unl Holdings Llc Drive mechanism for drug delivery pumps with integrated status indication
    CA2845379C (en) 2011-09-02 2019-08-06 Unitract Syringe Pty Ltd Insertion mechanism for a drug delivery pump
    BR112014004530A2 (en) 2011-09-02 2017-03-28 Unitract Syringe Pty Ltd drive mechanism for integrated state indication drug delivery pumps
    US9707335B2 (en) 2011-09-02 2017-07-18 Unitract Syringe Pty Ltd Drive mechanism for drug delivery pumps with integrated status indication
    US11173244B2 (en) 2011-09-02 2021-11-16 Unl Holdings Llc Drive mechanism for drug delivery pumps with integrated status indication
    JP6411888B2 (en) * 2011-09-07 2018-10-24 スリーエム イノベイティブ プロパティズ カンパニー Delivery system for hollow microneedle array
    US8808230B2 (en) 2011-09-07 2014-08-19 Asante Solutions, Inc. Occlusion detection for an infusion pump system
    JP2014528791A (en) 2011-09-13 2014-10-30 ユニトラクト シリンジ プロプライエタリイ リミテッドUnitract Syringe Pty Ltd Sterile fluid path connection to a drug container for a drug delivery pump
    WO2013050277A1 (en) 2011-10-05 2013-04-11 Unomedical A/S Inserter for simultaneous insertion of multiple transcutaneous parts
    EP2583715A1 (en) 2011-10-19 2013-04-24 Unomedical A/S Infusion tube system and method for manufacture
    US9440051B2 (en) 2011-10-27 2016-09-13 Unomedical A/S Inserter for a multiplicity of subcutaneous parts
    US8771229B2 (en) 2011-12-01 2014-07-08 Picolife Technologies, Llc Cartridge system for delivery of medicament
    US8790307B2 (en) 2011-12-01 2014-07-29 Picolife Technologies, Llc Drug delivery device and methods therefor
    US9402570B2 (en) 2011-12-11 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor devices, connections, and methods
    US10335545B2 (en) 2012-01-31 2019-07-02 West Pharma. Services IL, Ltd. Time dependent drug delivery apparatus
    WO2013134279A1 (en) 2012-03-05 2013-09-12 Becton, Dickinson And Company Wireless communication for on-body medical devices
    US10130759B2 (en) 2012-03-09 2018-11-20 Picolife Technologies, Llc Multi-ported drug delivery device having multi-reservoir cartridge system
    MX2014010944A (en) 2012-03-12 2014-11-13 Unitract Syringe Pty Ltd Fill-finish cartridges for sterile fluid pathway assemblies and drug delivery devices incorporating fill-finish cartridges.
    US9463280B2 (en) 2012-03-26 2016-10-11 Medimop Medical Projects Ltd. Motion activated septum puncturing drug delivery device
    US9072827B2 (en) 2012-03-26 2015-07-07 Medimop Medical Projects Ltd. Fail safe point protector for needle safety flap
    US10668213B2 (en) 2012-03-26 2020-06-02 West Pharma. Services IL, Ltd. Motion activated mechanisms for a drug delivery device
    WO2013146215A1 (en) * 2012-03-30 2013-10-03 テルモ株式会社 Medical solution administration device
    EP2833944A4 (en) 2012-04-06 2016-05-25 Antares Pharma Inc Needle assisted jet injection administration of testosterone compositions
    EP2650032A1 (en) * 2012-04-11 2013-10-16 PharmaSens AG Subcutaneous needle insertion mechanism
    IN2014DN08619A (en) 2012-04-13 2015-05-22 Becton Dickinson Co
    US9883834B2 (en) 2012-04-16 2018-02-06 Farid Amirouche Medication delivery device with multi-reservoir cartridge system and related methods of use
    US9364610B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Injection device with cammed ram assembly
    US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
    US9522235B2 (en) 2012-05-22 2016-12-20 Kaleo, Inc. Devices and methods for delivering medicaments from a multi-chamber container
    US10245420B2 (en) 2012-06-26 2019-04-02 PicoLife Technologies Medicament distribution systems and related methods of use
    US8454557B1 (en) 2012-07-19 2013-06-04 Asante Solutions, Inc. Infusion pump system and method
    US8454562B1 (en) 2012-07-20 2013-06-04 Asante Solutions, Inc. Infusion pump system and method
    US9867929B2 (en) 2012-08-15 2018-01-16 Becton, Dickinson And Company Pump engine with metering system for dispensing liquid medication
    WO2014036285A2 (en) 2012-08-29 2014-03-06 Unitract Syringe Pty Ltd Variable rate controlled delivery drive mechanisms for drug delivery pumps
    USD745142S1 (en) 2012-08-30 2015-12-08 Unitract Syringe Pty Ltd Drug delivery pump
    WO2014046950A1 (en) 2012-09-24 2014-03-27 Enable Injections, Llc Medication vial and injector assemblies and methods of use
    US9321581B2 (en) 2012-10-12 2016-04-26 Eli Lilly And Company Process and device for delivery of fluid by chemical reaction
    AU2013328883B2 (en) 2012-10-12 2018-08-02 Eli Lilly And Company Chemical engines and methods for their use, especially in the injection of highly viscous fluids
    US9427523B2 (en) 2012-12-10 2016-08-30 Bigfoot Biomedical, Inc. Infusion pump system and method
    US20140276536A1 (en) 2013-03-14 2014-09-18 Asante Solutions, Inc. Infusion Pump System and Methods
    US10549079B2 (en) 2012-12-21 2020-02-04 3M Innovative Properties Company Adhesive assemblies and microneedle injection apparatuses comprising same
    US9421323B2 (en) 2013-01-03 2016-08-23 Medimop Medical Projects Ltd. Door and doorstop for portable one use drug delivery apparatus
    USD723157S1 (en) 2013-03-12 2015-02-24 Unitract Syringe Pty Ltd Drug delivery pump
    JP6273655B2 (en) 2013-01-25 2018-02-07 ユーエヌエル ホールディングス エルエルシーUNL Holdings LLC Integrated fluid pathway connection and drug container
    DK2953667T3 (en) 2013-02-11 2020-01-27 Antares Pharma Inc Needle-assisted jet injection device with reduced triggering power
    US9446186B2 (en) 2013-03-01 2016-09-20 Bigfoot Biomedical, Inc. Operating an infusion pump system
    ES2742046T3 (en) 2013-03-11 2020-02-12 Antares Pharma Inc Dose injector with pinion system
    US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
    US10201662B2 (en) 2013-04-10 2019-02-12 Sanofi Injection device and assembly method
    US9011164B2 (en) 2013-04-30 2015-04-21 Medimop Medical Projects Ltd. Clip contact for easy installation of printed circuit board PCB
    US9889256B2 (en) 2013-05-03 2018-02-13 Medimop Medical Projects Ltd. Sensing a status of an infuser based on sensing motor control and power input
    ES2935038T3 (en) 2013-05-03 2023-03-01 Becton Dickinson Co drug delivery device
    US9446187B2 (en) 2013-06-03 2016-09-20 Bigfoot Biomedical, Inc. Infusion pump system and method
    US9457141B2 (en) 2013-06-03 2016-10-04 Bigfoot Biomedical, Inc. Infusion pump system and method
    DK3010568T3 (en) 2013-06-18 2019-05-06 Enable Injections Inc Device for transfer with vial and injection
    US9561324B2 (en) 2013-07-19 2017-02-07 Bigfoot Biomedical, Inc. Infusion pump system and method
    MX370074B (en) 2013-08-23 2019-11-29 Unitract Syringe Pty Ltd Integrated pierceable seal fluid pathway connection and drug containers for drug delivery pumps.
    US9119939B2 (en) * 2013-09-12 2015-09-01 Michael J. Botich Rotatable hypodermic needle and method of use
    AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
    US10569015B2 (en) 2013-12-02 2020-02-25 Bigfoot Biomedical, Inc. Infusion pump system and method
    CA2933166C (en) 2013-12-31 2020-10-27 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
    EP3102259B1 (en) 2014-02-03 2020-03-25 UNL Holdings LLC Expanding plunger rods for syringes
    GB201402261D0 (en) * 2014-02-10 2014-03-26 Owen Mumford Ltd Injector apparatus
    CN104888288A (en) 2014-03-07 2015-09-09 精工爱普生株式会社 Skin-patch type infusion pump
    US10004845B2 (en) 2014-04-18 2018-06-26 Becton, Dickinson And Company Split piston metering pump
    EP3151883A1 (en) 2014-06-03 2017-04-12 Amgen Inc. Devices and methods for assisting a user of a drug delivery device
    US9629901B2 (en) 2014-07-01 2017-04-25 Bigfoot Biomedical, Inc. Glucagon administration system and methods
    US9416775B2 (en) 2014-07-02 2016-08-16 Becton, Dickinson And Company Internal cam metering pump
    US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
    US10137246B2 (en) 2014-08-06 2018-11-27 Bigfoot Biomedical, Inc. Infusion pump assembly and method
    US9919096B2 (en) 2014-08-26 2018-03-20 Bigfoot Biomedical, Inc. Infusion pump system and method
    US11464899B2 (en) 2014-08-28 2022-10-11 Becton, Dickinson And Company Wireless communication for on-body medical devices
    EP3193974A1 (en) * 2014-09-15 2017-07-26 Sanofi Injection devices with tissue sewelling detection
    EP3193973A1 (en) * 2014-09-15 2017-07-26 Sanofi Medicament delivery device with rotatable housing on a base
    EP3197336B1 (en) 2014-09-25 2020-12-23 Progenity, Inc. Electromechanical pill device with localization capabilities
    AU2015323994A1 (en) 2014-09-29 2017-05-18 Unl Holdings Llc Rigid needle insertion mechanism for a drug delivery pump
    US10159786B2 (en) 2014-09-30 2018-12-25 Perqflo, Llc Hybrid ambulatory infusion pumps
    WO2016054015A1 (en) * 2014-09-30 2016-04-07 The Regents Of The University Of California Active agent delivery devices and methods of using the same
    JP6282209B2 (en) * 2014-10-08 2018-02-21 日本ライフライン株式会社 Chemical ablation device and chemical ablation system
    TWD174377S (en) 2014-11-07 2016-03-11 優尼翠克注射器有限公司 Portion of drug delivery device (1)
    EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
    US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
    WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
    EP3258989B1 (en) 2015-02-18 2020-01-01 Medtronic Minimed, Inc. Ambulatory infusion pump with static and dynamic seals
    US9795534B2 (en) 2015-03-04 2017-10-24 Medimop Medical Projects Ltd. Compliant coupling assembly for cartridge coupling of a drug delivery device
    US10251813B2 (en) 2015-03-04 2019-04-09 West Pharma. Services IL, Ltd. Flexibly mounted cartridge alignment collar for drug delivery device
    JP6799001B2 (en) 2015-03-10 2020-12-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Injection device
    CA2980004C (en) 2015-03-24 2023-10-10 Kaleo, Inc. Devices and methods for delivering a lyophilized medicament
    US10293120B2 (en) 2015-04-10 2019-05-21 West Pharma. Services IL, Ltd. Redundant injection device status indication
    US9744297B2 (en) 2015-04-10 2017-08-29 Medimop Medical Projects Ltd. Needle cannula position as an input to operational control of an injection device
    US9878097B2 (en) 2015-04-29 2018-01-30 Bigfoot Biomedical, Inc. Operating an infusion pump system
    US10213139B2 (en) 2015-05-14 2019-02-26 Abbott Diabetes Care Inc. Systems, devices, and methods for assembling an applicator and sensor control device
    CA2984939A1 (en) 2015-05-14 2016-11-17 Abbott Diabetes Care Inc. Compact medical device inserters and related systems and methods
    US10149943B2 (en) 2015-05-29 2018-12-11 West Pharma. Services IL, Ltd. Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly
    USD794770S1 (en) 2015-06-26 2017-08-15 Unitract Syringe Pty Ltd Drug delivery pump
    EP3316928B1 (en) 2015-06-30 2022-10-19 Kaleo, Inc. Auto-injectors for administration of a medicament within a prefilled syringe
    FR3038232B1 (en) * 2015-06-30 2017-07-28 Crossject INJECTION DEVICE WITHOUT NEEDLE EQUIPPED WITH A COMPRESSION SPRING
    FR3038231B1 (en) * 2015-06-30 2017-07-28 Crossject NEEDLE-FREE INJECTION DEVICE EQUIPPED WITH IMPROVED SEALING MEMBRANE
    USD794771S1 (en) 2015-07-10 2017-08-15 Unitract Syringe Pty Ltd. Drug delivery pump
    USD776264S1 (en) 2015-07-30 2017-01-10 Becton, Dickinson And Company Medical injector
    USD774640S1 (en) 2015-07-30 2016-12-20 Becton, Dickinson And Company Medical injector
    USD767120S1 (en) 2015-07-30 2016-09-20 Becton, Dickinson And Company Medical injector
    USD776263S1 (en) 2015-07-30 2017-01-10 Becton, Dickinson And Company Medical injector
    USD794776S1 (en) 2015-07-30 2017-08-15 Becton, Dickinson And Company Medical injector
    USD776262S1 (en) 2015-07-30 2017-01-10 Becton, Dickinson And Company Medical injector
    USD776265S1 (en) 2015-07-30 2017-01-10 Becton, Dickinson And Company Medical injector
    CN107029317B (en) * 2015-07-31 2020-07-28 重庆倍加医疗器械有限公司 Medicine injector
    US10576207B2 (en) 2015-10-09 2020-03-03 West Pharma. Services IL, Ltd. Angled syringe patch injector
    US9987432B2 (en) 2015-09-22 2018-06-05 West Pharma. Services IL, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
    US10086145B2 (en) 2015-09-22 2018-10-02 West Pharma Services Il, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
    CN108430536B (en) * 2015-10-09 2022-04-08 西医药服务以色列分公司 Method of filling a custom syringe
    HUE056371T2 (en) * 2015-11-11 2022-02-28 Hoffmann La Roche Transfilling device
    DK3380151T3 (en) * 2015-11-27 2021-01-25 Sanofi Aventis Deutschland DEVICE FOR INJECTION OF MEDICINAL PRODUCTS WITH A ROTARY NEEDLE HOLDER
    CA3009853C (en) * 2015-12-29 2023-08-01 Gajanan Kulkarni Transdermal microneedle drug delivery device and method
    US10449294B1 (en) 2016-01-05 2019-10-22 Bigfoot Biomedical, Inc. Operating an infusion pump system
    CA3009409A1 (en) 2016-01-05 2017-07-13 Bigfoot Biomedical, Inc. Operating multi-modal medicine delivery systems
    JP6885960B2 (en) 2016-01-21 2021-06-16 ウェスト ファーマ サービシーズ イスラエル リミテッド Drug delivery device with visual indicators
    WO2017127215A1 (en) 2016-01-21 2017-07-27 Medimop Medical Projects Ltd. Needle insertion and retraction mechanism
    CN111544704B (en) 2016-01-21 2022-06-03 西医药服务以色列有限公司 Force containment in autoinjectors
    JP7069023B2 (en) 2016-02-12 2022-05-17 メドトロニック ミニメド インコーポレイテッド Carrying injection pump and assembly for use with it
    USD809134S1 (en) 2016-03-10 2018-01-30 Bigfoot Biomedical, Inc. Infusion pump assembly
    WO2017161076A1 (en) 2016-03-16 2017-09-21 Medimop Medical Projects Ltd. Staged telescopic screw assembly having different visual indicators
    US10376647B2 (en) 2016-03-18 2019-08-13 West Pharma. Services IL, Ltd. Anti-rotation mechanism for telescopic screw assembly
    US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
    EP3463510B1 (en) * 2016-05-26 2019-11-13 Insulet Corporation Single dose drug delivery device
    GB2550924A (en) 2016-05-31 2017-12-06 Ndm Technologies Ltd Improvements in or relating to transdermal delivery
    JP6957525B2 (en) 2016-06-02 2021-11-02 ウェスト ファーマ サービシーズ イスラエル リミテッド Needle evacuation by 3 positions
    JP6869327B2 (en) 2016-08-01 2021-05-12 ウェスト ファーマ サービシーズ イスラエル リミテッド Anti-rotation cartridge
    EP3490635B1 (en) 2016-08-01 2021-11-17 West Pharma. Services Il, Ltd. Partial door closure prevention spring
    IL264404B (en) 2016-08-08 2022-07-01 Unitract Syringe Pty Ltd Drug delivery device and method for connecting a fluid flowpath
    WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
    US10695487B2 (en) 2016-08-30 2020-06-30 Unl Holdings Llc Controlled delivery drive mechanisms for drug delivery pumps
    EP3509469A1 (en) 2016-09-09 2019-07-17 Progenity, Inc. Electromechanical ingestible device for delivery of a dispensable substance
    US10926025B2 (en) 2016-09-15 2021-02-23 Tandem Diabetes Care, Inc. Vial supporter for medicament pump
    USD851244S1 (en) 2016-09-26 2019-06-11 West Pharma. Services IL, Ltd. Syringe barrel
    USD838367S1 (en) 2016-09-26 2019-01-15 West Pharma. Services IL, Ltd. Syringe barrel
    US20200016333A1 (en) * 2016-09-27 2020-01-16 Sanofi-Aventis Deutschland Gmbh A medicament delivery device
    US10426896B2 (en) 2016-09-27 2019-10-01 Bigfoot Biomedical, Inc. Medicine injection and disease management systems, devices, and methods
    EP3305349B1 (en) 2016-10-10 2020-09-23 Medimop Medical Projects Ltd Pharmaceutical cartridge
    US10610639B2 (en) 2016-10-10 2020-04-07 West Pharma. Services IL, Ltd. Needle insertion and retraction mechanism
    GB2556633A (en) * 2016-11-18 2018-06-06 Owen Mumford Ltd Medicament delivery device
    AU2017373857A1 (en) * 2016-12-05 2019-06-13 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
    EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
    USD836769S1 (en) 2016-12-12 2018-12-25 Bigfoot Biomedical, Inc. Insulin delivery controller
    AU2017376111B2 (en) 2016-12-12 2023-02-02 Bigfoot Biomedical, Inc. Alarms and alerts for medication delivery devices and related systems and methods
    WO2018119218A1 (en) 2016-12-23 2018-06-28 Kaleo, Inc. Medicament delivery device and methods for delivering drugs to infants and children
    WO2018136898A1 (en) 2017-01-23 2018-07-26 Abbott Diabetes Care Inc. Systems, devices and methods for analyte sensor insertion
    US11925790B2 (en) 2017-02-17 2024-03-12 Eli Lilly And Company Processes and devices for delivery of fluid by chemical reaction
    CA3055762A1 (en) 2017-03-31 2018-10-04 Progenity, Inc. Localization systems and methods for an ingestible device
    FR3064919B1 (en) * 2017-04-10 2020-07-10 Aptar France Sas DEVICE FOR AUTOMATIC INJECTION OF FLUID PRODUCT.
    JP7169991B2 (en) 2017-05-05 2022-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド self-injector
    CN110869072B (en) 2017-05-30 2021-12-10 西部制药服务有限公司(以色列) Modular drive mechanism for a wearable injector
    USD839294S1 (en) 2017-06-16 2019-01-29 Bigfoot Biomedical, Inc. Display screen with graphical user interface for closed-loop medication delivery
    US11389088B2 (en) 2017-07-13 2022-07-19 Bigfoot Biomedical, Inc. Multi-scale display of blood glucose information
    EP3664863A2 (en) * 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
    CA3073835A1 (en) 2017-08-30 2019-03-07 Pirouette Medical LLC Compact auto-injector
    EP3681562B1 (en) * 2017-09-15 2020-12-23 West Pharma. Services Il, Ltd. Patch injector
    WO2019071129A1 (en) 2017-10-05 2019-04-11 Pirouette Medical LLC Protective case for an auto-injector
    WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
    JP7402799B2 (en) 2017-12-22 2023-12-21 ウェスト ファーマ サービシーズ イスラエル リミテッド Syringes available with different cartridge sizes
    US11583633B2 (en) 2018-04-03 2023-02-21 Amgen Inc. Systems and methods for delayed drug delivery
    WO2019232077A1 (en) 2018-05-29 2019-12-05 Chrono Therapeutics Inc. Drug delivery methods and systems
    EP3866892A4 (en) * 2018-10-16 2022-07-20 Koglo Ltd. System and method for substance delivery
    CN116726361A (en) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 Methods and devices for treating diseases with biologic therapeutic agents
    KR20210109582A (en) * 2018-12-27 2021-09-06 폴리 메디큐어 리미티드 needle with safety mechanism
    US20220062533A1 (en) * 2019-01-07 2022-03-03 Shl Medical Ag Medicament delivery device
    USD1002852S1 (en) 2019-06-06 2023-10-24 Abbott Diabetes Care Inc. Analyte sensor device
    EP4009936A4 (en) 2019-08-09 2023-08-09 Kaleo, Inc. Devices and methods for delivery of substances within a prefilled syringe
    CN115666704A (en) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 Ingestible device for delivery of therapeutic agents to the gastrointestinal tract
    USD999913S1 (en) 2020-12-21 2023-09-26 Abbott Diabetes Care Inc Analyte sensor inserter
    USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector

    Family Cites Families (47)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US2390246A (en) * 1940-10-18 1945-12-04 Marvin L Folkman Syringe
    US2408323A (en) * 1943-06-10 1946-09-24 Margaret L Lockhart Hypodermic syringe
    US2545017A (en) * 1947-06-02 1951-03-13 Gordon D Billingsley Hypodermic syringe
    US2605765A (en) * 1947-06-05 1952-08-05 Kollsman Paul Automatic syringe
    US2576951A (en) * 1950-09-29 1951-12-04 Compule Corp Hypodermic syringe assemblies, including plural-compartment admixing ampoules for segregated storage of ingredients of liquid mediginal solutions and parts thereof
    GB718837A (en) * 1951-07-18 1954-11-24 Cook Waite Lab Inc Improvements in or relating to hypodermic syringe
    US2880723A (en) * 1954-02-09 1959-04-07 Becton Dickinson Co Syringe assembly
    GB995605A (en) * 1960-08-04 1965-06-23 Amalgamated Dental Co Ltd Improvements relating to hypodermic injection apparatus
    FR2243705A1 (en) * 1973-09-14 1975-04-11 Mussard Pierre Dental syringe for painless injections - with simultaneous penetration of needle and ejection of anaesthetic liq
    US4140117A (en) * 1975-05-12 1979-02-20 Alza Corporation Cartridge for liquid infusion apparatus
    US4403987A (en) * 1982-01-25 1983-09-13 Gottinger Company, Inc. Device for aiding injection of a hypodermic syringe
    EP0098592A3 (en) * 1982-07-06 1985-08-21 Fujisawa Pharmaceutical Co., Ltd. Portable artificial pancreas
    US4753651A (en) * 1982-08-30 1988-06-28 Alza Corporation Self-driven pump
    US4522622A (en) * 1982-12-23 1985-06-11 Alza Corporation Multiple fluid pulse dispenser
    US4622031A (en) * 1983-08-18 1986-11-11 Drug Delivery Systems Inc. Indicator for electrophoretic transcutaneous drug delivery device
    US4697622A (en) * 1984-06-01 1987-10-06 Parker Hannifin Corporation Passive filling device
    US4684365A (en) * 1985-01-24 1987-08-04 Eaton Corporation Disposable refill unit for implanted medication infusion device
    US4627445A (en) * 1985-04-08 1986-12-09 Garid, Inc. Glucose medical monitoring system
    US4687423A (en) * 1985-06-07 1987-08-18 Ivac Corporation Electrochemically-driven pulsatile drug dispenser
    CA1283827C (en) * 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
    US4734092A (en) * 1987-02-18 1988-03-29 Ivac Corporation Ambulatory drug delivery device
    US4902278A (en) * 1987-02-18 1990-02-20 Ivac Corporation Fluid delivery micropump
    US5070886A (en) * 1988-01-22 1991-12-10 Safety Diagnostice, Inc. Blood collection and testing means
    US4894054A (en) * 1988-06-20 1990-01-16 Miskinyar Shir A Preloaded automatic disposable syringe
    IT1231916B (en) * 1989-05-29 1992-01-15 Ampliscientifica S R L WEARABLE ARTIFICIAL PANCREAS
    FR2649617A1 (en) * 1989-07-12 1991-01-18 Veprol DEVICE FOR DELIVERING A PHARMACOLOGICAL ACTIVE PRINCIPLE BY ELECTROLYTIC PUMPING
    US5146091A (en) * 1990-04-19 1992-09-08 Inomet, Inc. Body fluid constituent measurement utilizing an interference pattern
    US5135507A (en) * 1990-05-10 1992-08-04 Habley Medical Technology Corporation One-piece syringe
    US5090963A (en) * 1990-10-19 1992-02-25 Product Development (Z.G.S.) Ltd. Electrochemically driven metering medicament dispenser
    US5279544A (en) * 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
    US5156591A (en) * 1990-12-13 1992-10-20 S. I. Scientific Innovations Ltd. Skin electrode construction and transdermal drug delivery device utilizing same
    SE9101022D0 (en) * 1991-01-09 1991-04-08 Paal Svedman MEDICAL SUSPENSION DEVICE
    US5562613A (en) * 1991-07-02 1996-10-08 Intermed, Inc. Subcutaneous drug delivery device
    JPH07502424A (en) * 1991-10-24 1995-03-16 インステック・インコーポレイテッド Gas pressure driven leaching device by hydrogel electrolysis
    US5336201A (en) * 1992-06-29 1994-08-09 Baxter International Inc. Syringe driving apparatus
    US5318557A (en) * 1992-07-13 1994-06-07 Elan Medical Technologies Limited Medication administering device
    US5267963A (en) * 1992-08-21 1993-12-07 Nicholas Bachynsky Medication injection device
    TW245642B (en) * 1992-09-29 1995-04-21 Alza Corp
    US5545143A (en) * 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
    JP3199524B2 (en) * 1993-08-06 2001-08-20 日本メジフィジックス株式会社 Luer needle unit and syringe
    FR2708858B1 (en) * 1993-08-09 1995-09-08 Zambon France Sa Infusion device with protective fins.
    US5582184A (en) * 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
    US5368578A (en) * 1994-03-10 1994-11-29 Sterling Winthrop Inc. Hypodermic syringe holder
    US5390671A (en) * 1994-03-15 1995-02-21 Minimed Inc. Transcutaneous sensor insertion set
    US5507730A (en) * 1994-10-04 1996-04-16 Habley Medical Technology Corporation One-piece glass prefilled syringe system
    US5568806A (en) * 1995-02-16 1996-10-29 Minimed Inc. Transcutaneous sensor insertion set
    CA2151407A1 (en) * 1995-06-09 1996-12-10 Duncan Newman Injection device

    Cited By (11)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US8070726B2 (en) 2003-04-23 2011-12-06 Valeritas, Inc. Hydraulically actuated pump for long duration medicament administration
    US9072828B2 (en) 2003-04-23 2015-07-07 Valeritas, Inc. Hydraulically actuated pump for long duration medicament administration
    US9125983B2 (en) 2003-04-23 2015-09-08 Valeritas, Inc. Hydraulically actuated pump for fluid administration
    US9511187B2 (en) 2003-04-23 2016-12-06 Valeritas, Inc. Hydraulically actuated pump for fluid administration
    US10525194B2 (en) 2003-04-23 2020-01-07 Valeritas, Inc. Hydraulically actuated pump for fluid administration
    US11642456B2 (en) 2003-04-23 2023-05-09 Mannkind Corporation Hydraulically actuated pump for fluid administration
    US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
    US8361053B2 (en) 2006-03-30 2013-01-29 Valeritas, Inc. Multi-cartridge fluid delivery device
    US8821443B2 (en) 2006-03-30 2014-09-02 Valeritas, Inc. Multi-cartridge fluid delivery device
    US9687599B2 (en) 2006-03-30 2017-06-27 Valeritas, Inc. Multi-cartridge fluid delivery device
    US10493199B2 (en) 2006-03-30 2019-12-03 Valeritas, Inc. Multi-cartridge fluid delivery device

    Also Published As

    Publication number Publication date
    DE69620257D1 (en) 2002-05-02
    WO1997021457A1 (en) 1997-06-19
    ATE214954T1 (en) 2002-04-15
    ZA9610374B (en) 1997-06-23
    EP0902696A1 (en) 1999-03-24
    CA2238614A1 (en) 1997-06-19
    TW317503B (en) 1997-10-11
    IL124470A0 (en) 1998-12-06
    US5858001A (en) 1999-01-12
    JP2000515394A (en) 2000-11-21
    AU1808797A (en) 1997-07-03
    DE69620257T2 (en) 2002-11-07

    Similar Documents

    Publication Publication Date Title
    EP0902696B1 (en) Cartridge-based drug delivery device
    EP1024845B1 (en) An improved automatic syringe
    US8684968B2 (en) Hypodermic drug delivery reservoir and apparatus
    EP0729366B9 (en) Intradermal drug delivery device
    US8608684B2 (en) Impulse chamber for jet delivery device
    CA3081685C (en) Low dose prefilled drug delivery device and method
    US20080215006A1 (en) Medical Device with Transcutaneous Cannula Device
    US20070049873A1 (en) Impulse chamber for jet delivery device
    US20040059316A1 (en) Medical delivery device
    US20010025168A1 (en) Pre-filled drug-delivery device and method of manufacture and assembly of same
    US7419484B2 (en) Administering device with an osmotic drive
    WO2004012796A1 (en) Medical delivery device
    EP3700610B1 (en) Injection device
    US7449009B2 (en) Device for needle-free injection of a medium into the tissue of a human or an animal, device for needle free production of an injection channel and method for the needle free injection of a medium in the tissue
    WO2005058392A2 (en) Cartridge for delivery device

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    17P Request for examination filed

    Effective date: 19980608

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    17Q First examination report despatched

    Effective date: 19990512

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: IF02

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AK Designated contracting states

    Kind code of ref document: B1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: NL

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20020327

    Ref country code: LI

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20020327

    Ref country code: GR

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20020327

    Ref country code: FI

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20020327

    Ref country code: CH

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20020327

    Ref country code: BE

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20020327

    Ref country code: AT

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20020327

    REF Corresponds to:

    Ref document number: 214954

    Country of ref document: AT

    Date of ref document: 20020415

    Kind code of ref document: T

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: EP

    REF Corresponds to:

    Ref document number: 69620257

    Country of ref document: DE

    Date of ref document: 20020502

    RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

    Owner name: ELAN CORPORATION, PLC

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FG4D

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: SE

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20020627

    Ref country code: PT

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20020627

    Ref country code: DK

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20020627

    ET Fr: translation filed
    NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

    Owner name: ELAN CORPORATION, PLC

    NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: ES

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20020925

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PL

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LU

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20021211

    Ref country code: IE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20021211

    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    26N No opposition filed

    Effective date: 20021230

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: MC

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20030701

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: MM4A

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: FR

    Payment date: 20110107

    Year of fee payment: 15

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GB

    Payment date: 20101229

    Year of fee payment: 15

    Ref country code: IT

    Payment date: 20101228

    Year of fee payment: 15

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: DE

    Payment date: 20101229

    Year of fee payment: 15

    GBPC Gb: european patent ceased through non-payment of renewal fee

    Effective date: 20111211

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: ST

    Effective date: 20120831

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R119

    Ref document number: 69620257

    Country of ref document: DE

    Effective date: 20120703

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: DE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20120703

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20111211

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: IT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20111211

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: FR

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20120102